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Summary 
Psoriasis is a common, relapsing inflammatory skin disease characterized by 
erythematous scaly plaques. It is thought to develop through a combination of genetic 
and environmental factors. Currently it is widely held that psoriasis is mediated by 
auto-aggressive helper T cells. Despite the availability of new effective drugs to treat 
psoriasis, the underlying mechanisms of its pathogenesis are still poorly understood. 
Recent studies have shown that Aldara cream, used to treat benign skin abnormalities, 
triggers psoriasis-like disease in humans and mice and have implicated TH17 cells in 
the disease initiation. Using this as a model, we found a predominant role for the 
TH17 signature cytokines IL-17A, IL-17F, and IL-22 in psoriasis-like plaque 
formation in mice. Using gene-targeted mice, it was observed that loss of Il17a, Il17f, 
or Il22 strongly reduced disease the severity of psoriasis. However, we found that 
TH17 cells were not the primary source of these pathogenic cytokines. Instead, IL-
17A, IL-17F, and IL-22 were produced by a skin-invading population of γδ T cells 
and RORγt+ innate lymphocytes. Furthermore, our findings establish that RORγt+ 
innate lymphocytes and γδ T cells are necessary and sufficient for psoriatic plaque 
formation in an experimental disease model that closely resembles human psoriatic 
plaque formation. These findings together with the matching clinical observations 
inevitably lead to a paradigm shift in our understanding of the human disease 
pathogenesis implicating epithelial stress responses and innate immunity to contribute 
to or even dominate the initiation of psoriasis. 
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Zusammenfassung 
Psoriasis ist eine häufige, rezidivierende entzündliche Hauterkrankung, die sich durch 
gerötete schuppige Plaques kennzeichnet und sich vermutlich durch eine Kombination 
von genetischen und umweltbedingten Faktoren entwickelt. Nach heutiger 
Lehrmeinung ist Psoriasis durch auto-aggressive T-Helfer-Zellen vermittelt. Trotz der 
Verfügbarkeit von neuen wirksamen Medikamenten zur Behandlung von Psoriasis, 
sind die zugrunde liegenden Mechanismen der Pathogenese noch weitgehend 
unverstanden. Jüngste Studien haben gezeigt, dass Aldara Creme – normalerweise 
eingesetzt zur Behandlung von gutartigen Hautveränderungen – eine Psoriasis-
ähnliche Krankheit auslöst. Sowohl bei Menschen als auch bei Mäusen scheinen 
TH17-Zellen zur Krankheitsentstehung beizutragen. In dieser experimentellen 
Psoriasis konnten wir eine herausragende Rolle für die TH17 Zytokine IL-17A, IL-
17F und IL-22 bei der Psoriasis-ähnlichen Plaquebildung bei Mäusen nachweisen. Bei 
Verwendung von transgenen Mäusen zeigte sich, dass der Verlust von IL-17A, IL-
17F oder IL-22 die Schwere der Erkrankung stark reduziert. Jedoch scheinen TH17 
Zellen nicht die Hauptquelle dieser pathogenen Zytokine zu sein. Stattdessen wurden 
IL-17A, IL-17F, und IL-22 durch eine Population von γδ T-Zellen und RORγt 
angeborenen Lymphozyten produziert, die in die Haut einwandern. Außerdem 
scheinen RORγt positive angeborene Lymphozyten und γδ T-Zellen für die Plaque-
Bildung in unserem Krankheitsmodell, welches die humane psoriatische 
Plaquebildung nachahmt, notwendig und ausreichend zu sein. Diese Ergebnisse, 
zusammen mit den passenden klinischen Beobachtungen, werden unweigerlich zu 
einem Paradigmenwechsel in unserem Verständnis der menschlichen 
Krankheitsentstehung führen: Epitheliale Stressreaktionen und angeborenen 
Immunität tragen dazu bei oder dominieren sogar die Entstehung der Psoriasis.
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Abbreviations  
 
 
APC  Antigen presenting cell  
ATP  Adenosine 5´-triphosphate  
CD  Cluster of differentiation 
CFA  Complete Freud’s adjuvant 
CLA  Cutaneous leukocyte antigen 
DC  Dendritic cell 
dDC  Dermal dendritic cell 
DETC  Dendritic epidermal T cell 
GM-CSF  Granulocyte Monocyte-colony 
stimulating factor 
GWAS  Genome-wide association studies 
H&E  Hematoxylin & Eosin 
HLA  Human leukocyte antigen 
i.v.   intravenous 
ICAM  intercellular adhesion molecule 1  
IFN  Interferon 
IL  Interleukin 
ILC  Innate lymphoid cell 
iNOS   Inducible nitic oxide synthase 
LTi   Lymphoid Tissue inducer 
mDC  Myeloid dendritic cell 
MHC  Major histocompatibility complex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MPO  Myeloperoxidase  
NF-κB  Nuclear factor-κB 
NK-cell  Natural killer cell  
NKT-cell  Natural killer T-cell 
PAMP  Pathogen associated molecular pattern 
PASI  Psoriasis area severity index 
PBS  Phosphate buffered saline 
pDC  Plasmacytoid dendritic cell 
RAG  Recombination activating gene 
ROS  Reactive oxygen species 
STAT  Signal transducer and activator of 
transcription 
TCR  T-cell receptor 
TGF-β  Transforming growth factor-β 
TLR Toll like receptor 
TNF  Tumor necrosis factor  
TNFR  Tumor necrosis factor receptor 
TH  T-helper cell 
Treg  Regulatory T-cell  
VCAM  Vascular adhesion molecule 
VEGF  Vascular endothelial growth factor 
WT  wild-type 
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1. Introduction 
The immune system has evolved under selective pressure from the pathogens. This 
resulted in multicellular organisms developing diverse mechanisms to protect 
themselves by detecting the microorganism and subsequently neutralizing or killing 
them. These mechanisms are old and highly conserved and are termed the innate 
immune system. Its recognition receptors are encoded within the genomes of the 
species1. 
On the other hand, the adaptive immune system relies on receptors, which are 
generated during maturation of each organism. This mechanism leads to de novo 
generation of a diverse repertoire of receptors with random specificities. As a result, 
the recognition of these receptors is highly specific, but at the same time it is 
determined by chance. This is also the case for the subsequent response of the cell in 
the event of receptor engagement. Different pathogenic insults require different and 
appropriate responses. Hence, the adaptive immune system requires informative 
signals from the innate immune system to mount or not and the type of immune 
response required2. Moreover, an accidental event of recognition of self-antigens by 
these receptors could lead to autoimmunity.  
Innate immune cells include dendritic cells (DCs), macrophages, and neutrophils, 
among others. The innate immune system is centered around recognition of pathogen-
associated molecular patterns (PAMPs), rather than specific organisms or antigens3. 
The PAMPs on the pathogens are recognized by the receptors encoded and expressed 
by the innate immune cells and are called pattern recognition receptors (PRRs)4. The 
most well-studied class of PRRs are the Toll-like receptors (TLRs)5. Engagement of 
the PRRs increases the phagocytic activity of the innate immune cells, which 
subsequently leads to the destruction of pathogens. It is thought that the innate 
immune system determines the origin of antigens through differential receptor signals. 
Subsequently, it coordinates the adaptive immune response by means of antigen 
presentation, costimulation as well as through production of cytokines and 
chemokines. The latter signals control the recruitment of leukocytes to the sites of 
insult and regulate the activation of appropriate effector mechanisms, for example by 
controlling differentiation of T lymphocytes into effector cells of a particular type6. 
The T and B lymphocytes are the two principle cell types that make up the adaptive 
Introduction   
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immune system. Only these cells express highly variable, randomly generated, 
clonally distributed antigen receptors and need antigen priming for effective antigen 
responses. B cells provide antibody responses, and T cells are the source of cell-
mediated immunity. The adaptive immune system evolved to  “remember” pathogenic 
insults, making the immune response more efficient and rapid. 
The generation of B cells occurs throughout life and takes place in the bone marrow. 
According to the clonal-selection hypothesis of Frank Macfarlane Burnet, recognition 
of foreign antigen by mature B cells should trigger clonal expansion and antibody 
secretion, thereby yielding immune specificity and memory. At the same time, 
reactivity to autoantigens early in development should trigger cell death, thereby 
ensuring tolerance to self7. B-cell tolerance is achieved by clonal deletion, cell 
inactivation (anergy) or receptor editing. Receptor editing is the dominant tolerance 
mechanism for developing B cells, and occurs during the immature B-cell stage, in 
the bone marrow8.  
At the same time, thymic selection processes shape the T-cell repertoire. During 
positive selection thymocytes that do not engage self-MHC molecules die by neglect. 
Later, negative selection eliminates thymocytes that have high-avidity interactions 
with APCs presenting a self-antigen, by clonal deletion9. Moreover, medium self-
reactive thymocytes can undergo anergy, T-cell receptor revision, through editing or 
be diverted to other lineages (Treg or CD8αα). Finally, thymocytes that have a TCR 
with low affinity for self-peptide–MHC complexes are positively selected to further 
differentiate and function in adaptive immunity, and this process is also known as 
central tolerance10. 
The large numbers of all body proteins are not expressed in the thymus or in the 
serum. The process of preventing self-reactivity after the lymphocytes leave the 
thymus/bone marrow is called peripheral tolerance. Autoreactive T and B-
lymphocytes may ignore the presence of their autoantigen due to low concentration of 
the antigen or immunoprivileged location of its expression. T cells are only able to 
recognize processed antigens presented in the context of MHC molecules11.  
Peripheral anergy results from naïve T cells encountering their antigen-MHC 
complex, but without co-stimulation. Autoreactive lymphocytes can also be 
eliminated by lymph node–resident immature dendritic cells that present tissue-
derived antigen. Finally, autoagressive T lymphocytes can be suppressed by 
regulatory T cells12. Despite all of these sophisticated and clever tolerance 
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mechanisms unwanted inflammation can still occur. The milder version results in 
allergy, but is, strictly speaking, not an autoimmune process13. Autoimmunity on the 
other hand can result in severe inflammation and currently seems to be on a rise14. 
The skin together with the mucosal surfaces act as important barriers to protect the 
body from the outside environment and microbial threats. To maintain the barrier 
integrity tight regulation and clockwork homeostasis are required to keep the skin 
barrier intact. However, when the barriers are breached, for example tissue injury, a 
rapid, but at the same time self-limiting immune response is required. Inadequate 
responses can lead to severe infections and tumourogenesis15, whereas excessive 
responses can result in chronic inflammation and autoimmunity. 
Psoriasis is a common skin and joint auto-inflammatory disease. It occurs from a 
complex combination and interplay of genetic predisposition and environmental 
factors that lead to excessive immune responses to a self or environmental antigen, 
resulting in chronic inflammation16,17. 
	  
1.1	  Clinical	  features	  and	  hallmarks	  of	  psoriasis	  	  
Psoriasis was originally thought to be variant of leprosy18 and it took until 1841 for it 
to be classified as a separate disease19,20. It is a chronic relapsing and remitting skin 
and joint disease that affects approximately 2-3% of the world’s 
population16,21.Psoriasis has a bimodal distribution with peaks between 15 and 30 
years, as well as 50 and 60 years22. 
 
1.1.1	  Epidemiology	  
The highest prevalence of psoriasis is observed in Caucasian North Americans, 
affecting nearly 5% of the population. At the same time only about 0.5% of Africans 
and Asians are affected16,21. A population study suggests that psoriasis has a negative 
effect on overall longevity even after all the common mortality factors are accounted 
for. This results in an overall decrease in life expectancy of 3.5 years in males and 4.4 
years in females20,23. The high morbidity in psoriasis patients results in its burden on 
the economy being similar to that of diabetes, cardiovascular diseases and CNS 
illnesses24-26. Increases in suicidal tendencies, depression and mental illnesses have 
also been attributed to psoriasis27. Moreover, income and employment are negatively 
impacted among patients with severe psoriasis compared with mild psoriasis 
Introduction   
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patients28.  
Psoriasis is generally limited to inflammation of the skin, but as many as 30% of the 
patients also suffer from debilitating psoriatic arthritis. At the same time psoriatic 
arthritis prevalence in the general population is around 1%29,30.  
Psoriasis has many well-established comorbidities, in particular cardiovascular 
diseases31,32. Severe psoriasis has been shown to be an independent risk factor for 
myocardial infarction in younger patients20,33. Other diseases associated with psoriasis 
are:  Crohn’s disease34, type II diabetes35, obesity36-38, metabolic syndrome39 and 
lymphoma40. 
 
1.1.2	  Clinical	  features	  	  
Psoriasis patients can show a wide variety of clinical phenotypes that represent a 
dynamic spectrum of a single disease (Figure 1)16,19,20. Most scientific research refers 
to the most common form of the disease called psoriasis vulgaris (Figures 1A, B, D) 
and accounts for nearly 90% of the cases21. The disease is generally manifested as 
raised, well-demarcated, erythematous oval plaques with adherent silvery scales20,41.  
The acute form of the disease, during initial eruptions may exhibit a guttate 
distribution pattern and is often triggered by streptococcal infections (Figure 1E)42,43. 
Inverse psoriasis is usually located at intertriginous areas and rarely displays any 
scaling (Figure 1C). Other versions such as generalized pustular psoriasis of von 
Zumbusch may also occur (Figure 1F)44.  
The classification of the disease has been historically based on the clinical appearance 
and mainly on plaque thickness45. Alternatively, psoriasis is classified according to 
HLA status, which determines type I and type II psoriasis46,47.  Type I psoriasis 
accounts for about 65% of the cases and generally occurs in younger fraction of the 
bimodal distribution, with a positive family history of the disease, preceded by 
streptococcal throat infection and guttate lesions. Type II psoriasis is associated with 
the older patients, with no family history of the disease. It is generally not linked to 
any preceding disease and tends to lead to involvement of nails and joints (Figure 
1G)20,48. 
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A B 
C 
D E 
F G 
Figure 1. Clinical images showing the spectrum of psoriasis phenotypes. The typical 
psoriatic lesion is a sharply demarcated erythematous plaque covered by silvery white 
scales, (A) often appearing on the elbows. (B) Scalp involvement is seen in approximately 
50 percent of patients with psoriasis. (C) Inverse psoriasis (D) Lesions may cover the 
entirety of the body (E) Guttate psoriasis is often triggered by streptococcal infections. (F) 
Pustular psoriasis. (G) Psoriatic arthritis (Adapted from Perera et.al., 2012; Nestle et. al., 
2009, and Schon and Boehncke 2005) 
Introduction   
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1.1.3	  Histological	  features	  	  
The thickening of the epidermis and the associated scales are due to premature 
keratinocyte maturation and subsequent incomplete cornification, leading to the 
retention of the nuclei in the stratum corneum (parakeratosis). Abnormal increase in 
the keratinocyte turnover causes thickening of the epidermis (acanthosis) and 
elongation of the epidermal rete ridges (papillomatosis), as well as loss of the granular 
layer (hypogranulosis)20,41. There is extensive new blood vessel formation49, which 
results in pinpoint bleeding upon damage to the scales. Finally, a mixed leukocytic 
infiltrate is seen in both dermis and epidermis, composed of DCs, CD4+ TH cells 
within the upper papillary dermis and CD8+ cytotoxic T cells within the epidermis50. 
The neutrophilic granulocytes transmigrate through the epidermis and form, a 
histopathological hallmark of psoriatic lesions, the Munro microabscesses19,51 (Figure 
2). 
 
	  1.2	  Genetics	  
The population and family studies that have started in 1960s showed that psoriasis 
occurs more often in relatives than within controls and general population52,53. The 
studies in twins have shown genetic predisposition to psoriasis as concordance in 
monozygotic twins was 35-70%, while only 12-20% in dizygotic twins54-56. No clear 
inheritance pattern and lack of 100% concordance in twins hints at a role of 
environmental factors in psoriasis pathogenesis57,58. Over the last half-century many 
advances have been made in understanding the genetic basis of psoriasis, identifying 
several predisposition loci and genes. These were identified using genome-wide scale 
and candidate-gene as well as genome-wide association studies (GWAS). 
 
1.2.1	  Psoriasis	  susceptibility	  (PSORS)	  
The major genome region associated with psoriasis is called psoriasis susceptibility 1 
(PSORS1). It is a 220 kb fragment, encoding the genes of the major 
histocompatibility complex (MHC), located on the short arm of chromosome 6 and 
contains 10 known genes59. This region was first identified as potential psoriasis 
locus, when serologic typing identified an association between psoriasis and the HLA-
Cw*602 allele of the MHC class I molecule human leukocyte antigen molecule HLA-
C60,61. Sequence, haplotype analyses62 and fine linkage mapping have linked HLA-C 
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variant HLA-Cw*060 to be the most probable PSORS1 gene. Using single nucleotide 
polymorphism (SNP) studies within the HLA-C gene it was later shown to have the 
greatest association with psoriasis in multiple GWAS63,64. However, at the same time 
these studies hinted at other potential determinants of psoriasis susceptibility within 
the MHC20. 
As many as 60% of psoriasis sufferers carry the HLA-Cw*602 gene-variant, which 
confers a stunning 20-fold-increased risk of developing psoriasis and is found in 10-
15% of the population65. Moreover, individuals homozygous for this gene variant are 
5 times more likely to develop the disease compared to heterozygous ones66. The 
Figure 2. Hematoxylin and eosin stainings showing histological features of psoriasis. 
(A) Normal skin. (B) Psoriatic skin showing acanthosis, elongation of epidermal rete 
ridges (arrowheads), marked hyperkeratosis, loss of the granular layer, and parakeratosis. 
Dermal blood vessels are increased in number and size. They are contorted and reach up 
to locations directly underneath the epidermis (arrows). (C) A mixed leukocytic infiltrate 
is seen in both dermis and epidermis. Neutrophilic granulocytes transmigrate through the 
epidermis and form Munro microabscesses underneath the stratum corneum (arrowhead). 
(D) As the lesions progress, these microabscesses are transported to the upper layers of the 
stratum corneum, where they slough off (arrow). Adapted from Schon and Boehncke 
2005. 
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patients with the HLA-Cw*602 allele are part of psoriasis type I group described 
above47,48. 
The exact role of HLA-Cw*602 and HLA-C in psoriasis is still unknown. This is due 
to high homology MHC class I genes and high degree of polymorphisms within HLA-
C, which impede functional studies20. As HLA-C is expressed on antigen presenting 
cells (APCs) it has the ability to influence both innate and adaptive immune systems. 
Through these molecules APCs can prime cytotoxic CD8+ T cells, which are 
commonly found in the psoriatic epidermis50. Moreover, keratinocytes that express 
HLA-C can interact with killer immunoglobulin-like receptors (KIRs). These 
molecules are expressed on NK and NKT cells and have both activating and 
inhibitory functions67. Interestingly, the latter cell type have recently been reported to 
play a role in psoriasis68. It is also possible that unique features of HLA-Cw*602 that 
affect its expression and/or activity can lead to modified innate and adaptive immune 
responses that eventually lead to psoriasis20. 
Even though PSORS1 confers the highest risk for the development of psoriasis, it is 
responsible for only about 50% of familial clustering. Other studies using linkage 
analyses of families with multiple psoriasis sufferers have identified another 9 
psoriasis susceptibility loci (PSORS2-10)20,46.  
Another region of strong association with psoriasis, PSORS2 is associated with 
chromosome 17q25 and is separated by 6 Mbp. The associated SNPs in the proximal 
peak lie in or near NAT9 gene, a member of the N-acetyltransferase family, and 
SLC9A3R1. SLC9A3R1 is implicated in diverse aspects of epithelial membrane 
biology and immune synapse formation in T cells. The distal peak of association is in 
RAPTOR, a target of rapamycin (TOR)-scaffold protein. Expression of SLC9A3R1 is 
highest in the uppermost stratum Malpighi of psoriatic and normal skin and in 
inactive versus active T cells. Another disease-associated SNP lies between 
SLC9A3R1 and NAT9, and leads to loss of RUNX1 transcription factor binding69-71.  
Psoriatic skin lesions demonstrate an activated IFN-α signaling pathway72. 
Continuous excessive IFN-α signaling in IFN regulatory factor deficient (IRF-2-/-) 
mice causes an inflammatory skin disease resembling psoriasis73. At the same time, 
treatment of psoriasis patients with recombinant IFN-α for unrelated conditions can 
exacerbate psoriasis74,75. Finally, in the xenotransplantation model of psoriasis 
blocking of IFN-α resulted in complete disease prevention76. Eventually all this 
evidence resulted in PSORS3 being mapped to the IRF2 gene on chromosome 4p, a 
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transcriptional repressor of type I interferon target genes77,78. 
Cystatin A is involved in regulation of the skin barrier. It is now believed to be one of 
the precursors of the cornified cell envelope formed during terminal differentiation of 
keratinocytes, thereby suggesting that cystatin A expression is associated with 
keratinocyte differentiation, which is impaired in psoriatic skin. Recently, cystatin A 
gene has been mapped to PSORS5 locus on chromosome 3q79,80. 
PSORS6, 8 and 9 loci are not as well characterized, but they have implicated 
JUNB81,82; CXCL1, CX3R1, CARD1571; and Il1583 genes, respectively, in the 
pathogenesis of psoriasis.  
 
1.2.2	  IL-­‐23/TH17	  Pathway	  genes	  
Many studies have shown a crucial role for IL-23 and TH17 cells in the pathogenesis 
of psoriasis84-86. IL-23 is a heterodimeric IL-12 family cytokine87. It consists of a 
unique IL23p19 subunit and IL12/23p40 subunit, shared with IL-12. Similarly, IL-23 
signals through a heterodimeric receptor composed of IL-23R and IL-12Rβ1 (Figure 
3). Receptor binding by IL-23 leads to a signaling cascade involving signal transducer 
and activator of transcription 3 (STAT-3)87.  
IL-23 plays a crucial role in TH17 cell differentiation, as well as induction of IL-17 
and IL-22 in other cell types88. Furthermore, this pathway has been identified to carry 
the major pathogenic functions in many autoimmune diseases89. 
Multiple studies have identified SNPs associated with psoriasis within IL12B and 
IL23R genes, which code for IL-12/23p40 and IL-23R, respectively90,91. Notably, 
IL23R actually lies within PSORS7 locus92. Disease associated SNPs within IL-23p19 
subunit gene, IL23A have also been identified64. 
One of the most well described polymorphisms identified by GWAS is guanine-to-
adenine missense SNP within IL23R, which results in Arg381-to-Gln within the 
cytoplasmic domain of IL-23R and is associated with protection against 
psoriasis64,90,91. The same substitution is also associated with protection from Crohn’s 
disease93 and ankylosing spondylitis94. 
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The more rare IL23R 381Gln gene variant accounts for threefold protection against 
Crohn’s disease95 and twofold protection against psoriasis96 and ankylosing 
spondylitis94. These findings also imply that this SNP may offer protection for many 
other autoimmune diseases, in which the IL-23/TH17 pathway is involved89,95. 
Functional studies of this substitution have shown that, despite it having no effects on 
TH17 cell numbers and activity, the effector functions of TH17 cells were lower in the 
protective allele carriers. STAT-3 activation and IL-17A secretion were reduced in 
response to IL-23 in the cells derived from the donors heterozygous for the protective 
allele97. Moreover, these findings are being used as a platform to investigate the 
possibility of using IL23R 381Gln variant as a biomarker to predict therapeutic 
responses20. 
 
1.2.3	  NF-­‐κB	  pathway	  genes	  
The NF-κB pathway is critical for immune responses and cell cycle regulation. The 
genes of this pathway encode for proinflammatory, cell cycle, antiapoptotic and 
Figure 3. Structures of IL-12, IL-23 and their receptors.  
Modified from Kastelein et.al., 2007 
  Introduction 
 
 23 
chronic inflammation mediators98,99.  In resting cells NF-κB proteins are localized in 
the cytoplasm and associate with inhibitory proteins of this signaling pathway, such as 
inhibitor of κB (IκB). This pathway can be triggered by a multitude of signals, 
including TNFα, IL-1, TLR signals, and free radicals. Upon activation of the 
signaling cascade IKK activation results in IκB phosphorylation and degradation, for 
the canonical pathway, or p100 processing to p52 for the noncanonical pathway. 
Phosphorylated NF-κB dimers bind to κB DNA elements and induce transcription of 
target genes99.  
Activation of NF-κB may play an important role in psoriasis, as multiple GWAS 
studies, have identified numerous SNPs within the genes coding for NF-κB signaling 
regulators. These include downstream TNF signaling genes TNFAIP364,100 and 
TNIP164,100,101. NFKBIA, which codes for α subunit of IκB100,102 and 
TRAF3IP2100,103,104, coding for adaptor molecule involved in IL-17 activation of NF-
κB signaling have also implicated the NF-κB pathway in psoriasis. TH17 and NF-κB 
are the two major proinflammatory pathways involved in psoriasis, and TRAF3IP2 
may represent a critical checkpoint regulating both the adaptive and innate immune 
responses that underpin psoriasis pathogenesis20. 
 
1.2.4	  Epidermal	  differentiation	  genes	  
PSORS4 accounts for a cluster of about 20 genes that are expressed during epidermal 
differentiation105,106, confirmed both by GWAS107 and genome-wide copy number 
variation analysis108. Of particular importance are three genes of the late cornified 
envelope (LCE) family. Interestingly, SNPs in the LCE cluster are associated with 
psoriasis in Chinese psoriasis patients107, while deletions of regions encoding for 
LCE3C and LCE3B are common in European psoriasis patients108. Moreover, LCE3C 
mRNA is significantly upregulated in wounded and psoriatic skin, indicating its 
importance in skin barrier repair20. 
 
1.2.5	  Other	  genes	  
Another important gene implicated in psoriasis susceptibility and replicated in 
multiple studies is ERAP1100,101. ERAP1 is an IFN-γ-induced aminopeptidase, 
involved in trimming peptide antigens for binding to MHC class I109. Accordingly, it 
influences psoriasis susceptibility only in individuals carrying HLA-C risk-associated 
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variant100. 
 
1.3	  Current	  understanding	  of	  the	  pathogenesis	  of	  psoriasis	  
Despite the exact triggers of psoriasis still unknown there are many associated 
triggers: streptococcal throat infection43,110; physical trauma, such as tattoos and 
scratches, also known as Koebner phenomenon111; some medications, including 
antidepressants, antihypertensives, and anticytokine treatments for other conditions112; 
smoking, obesity and alcohol20. 
The current understanding of the pathogenesis of psoriasis implicates complex 
interplay between disruption of the skin barrier and deregulated immune 
compartment, which results in extended inflammatory response20. Moreover, there are 
many parallels between skin healing and psoriasis, which leads many to believe that 
psoriatic lesions represent a prolonged wound-healing process113-115. 
Currently, there is still an ongoing argument about the dominant cell type in psoriasis 
pathogenesis, with keratinocytes and T cells as primary suspects. At the same time if 
innate or adaptive immune responses are more important for the disease 
development20. Complicating it even further is the dynamic nature of psoriasis, which 
makes it likely that different cell types play different roles during initiation, 
progression, maintenance and remission of the disease46. In addition, despite general 
agreement about a role of T cells in psoriasis, no foreign antigens or autoantigens 
have been identified and yet autoimmune nature of psoriasis has long been 
postulated116. Only very recently this theory has received a boost, when self-DNA and 
self-RNA were found to induce proinflammatory cytokine signals117. 
Cell types that have been identified within psoriatic lesions include mDCs, pDCs, 
macrophages, neutrophils and T cells, with apparent increased vascularisation118-120. 
In the presence of an altered and deregulated keratinocyte barrier, these cells continue 
to orchestrate an aberrant immune response to an unknown antigen, resulting in the 
development of psoriasis20. 
 
1.3.1	  Keratinocytes	  
Keratinocytes are the main constituents of the epidermis. In addition, to their 
structural and mechanical barrier functions, they have an important role in regulation 
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of the inflammation in the skin121. Similar to the innate immune system they respond 
to pathogenic insults in a rapid nonspecific manner. Despite not being professional 
APCs keratinocytes are able to process and present antigens to T cells. There is also 
close association between Langerhans cells, T cells and keratinocytes in the 
skin122,123. 
The major factor determining the immune activity of keratinocytes in normal or 
diseased skin is their state of activation or differentiation. Terminally differentiated 
keratinocytes are important for mechanical integrity of the skin barrier as well as 
protection against pathogens and immune responses against those124. Under normal 
conditions, differentiation is favoured and only basal keratinocytes can regenerate and 
differentiate through the spinous and granular layers of the epidermis to become 
corneocytes20. 
In psoriasis, terminal differentiation of keratinocytes is not complete and keratinocyte 
stem cell proliferation is deregulated, resulting in preferential activation and 
proliferation of cells that mature too quickly, but differentiate incompletely120. This 
leads to increased responses to cytokines and growth factors, which is also observed 
in wound healing. Activated keratinocytes display different phenotype compared to 
terminally differentiated ones, they are hyperproliferative and display migratory 
features. Additionally, they can rearrange their cytoskeleton, increase the expression 
levels of cell surface receptors and secrete components of the basement membrane. 
Moreover, activated keratinocytes are able to produce cytokines, proangiogenic 
molecules, such as VEGF, which help to restore tissue integrity and recruit of 
circulating leukocytes49,125. Upon successful repair of the skin barrier keratinocytes 
are deactivated and return to their differentiated state, which is not the case in 
psoriasis126. 
 
1.3.1.1	  IL-­‐1	  Family	  members	  and	  the	  inflammasome	  
The critical factor for keratinocyte activation is IL-1, which is important for many 
inflammatory responses to injury127. Isoforms of IL-1, termed α and β, are stored in 
the cytoplasm in their inactive pro-forms, under normal conditions128-131. When PRRs 
are triggered, caspase-1 is activated within the inflammasome of keratinocytes132, 
resulting in cleavage of IL-1 isoforms, as well as pro-IL-18 into their active forms133. 
Injured or activated keratinocytes release active IL-1, thus allowing the neighboring 
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skin cells to respond to the insult by amplifying the response through further secretion 
of IL-1, TNFα, IL-6 and other proinflammatory mediators134-136. 
Apart from having proinflammatory effects on surrounding cells IL-1 also acts as a 
chemoattractant for lymphocytes, enabling them to extravasate and migrate to the 
injured areas137. This is additionally mediated through induction of selectin expression 
on endothelial cells, allowing lymphocytes to slow down, firmly attach and 
subsequently enter the damaged tissues. Moreover, IL-1 has further effects on T cells, 
by skewing them towards IL-17 production138,139. At the same time another member 
of this family, IL-18 promotes polarization towards TH1 phenotype140. A microarray 
study showed that many members of IL-1 family, including IL-1F6, IL-1F8 and IL-
1F9 are upregulated in psoriatic skin141,142.  
In psoriatic lesions keratinocytes also produce other immune mediators such as 
intercellular adhesion molecule 1 (ICAM-1), CD40, HLA-DR and S100 family 
proteins, which act as chemotactic factors for leukocytes143. At the same time there is 
a positive feedback loop resulting in infiltrating leukocytes further upregulating the 
above molecules46,118,123. Additionally, the leukocytes that have already entered the 
skin and keratinocytes produce chemokines, resulting in even more recruitment of the 
immune cells into the skin. Most notably, these are CCL27, ligand for CCR10, which 
is expressed by 90% of skin-infiltrating lymphocytes144, as well as CCL4, CCL20, 
CXCL2, and IL-8145. Furthermore, keratinocytes can activate T cells directly through 
their expression of MHCII, ICAM-1 and B7-H1146. 
 
1.3.1.2	  Antimicrobial	  peptides	  
Another very important component of keratinocyte immune responses are 
antimicrobial peptides, which have been shown to be highly upregulated in psoriatic 
skin147. There are multiple families of these peptides: cationic cathelicidins, defensins, 
S100 proteins, peptidoglycan recognition proteins, C-type lectins and iron-
metabolizing proteins148. Antimicrobial peptides can also act as immune mediators149, 
opsonins and chemokines150,151. IL-1 and IL-18 are both strong inducers of 
antimicrobial peptides152,153. One of these, LL-37 synergizes with IL-1 to induce even 
more cytokine and chemokine production, subsequently resulting in increased 
recruitment of neutrophils and macrophages, leading to even more 
inflammation47,48,154. 
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1.3.1.3	  Angiogenesis	  
Psoriatic skin is highly vascularized and development of high endothelial venules, 
usually associated with lymph nodes, is observed20. The blood vessels in the lesional 
skin are dilated and are highly permeable due to nitric oxide, produced by 
inflammatory DCs155. Higher vascularization is able to support more keratinocytes 
and also results in more leukocytes being recruited to the skin through higher levels of 
ICAM-1, vascular adhesion molecule 1 (VCAM-1) and E-selectin125. 
At the same time VEGF maintains endothelial cell integrity and induces their 
migration, survival, proliferation and its levels are increased in the sera of psoriasis 
patients, compared to healthy controls156. It’s role in psoriasis is further supported 
through successes of antiangiogenic drugs such as AE-491 and paclitaxel157,158. 
 
1.3.2	  Cells	  of	  the	  immune	  system	  
Many immune cells are associated with the psoriatic lesions, but as with many 
immune responses APCs are thought to respond to the initial trigger. These cells 
include including pDCs, mDCs, Langerhans cells and dermal resident DCs (dDCs). 
On the other hand the key effector cells activated by DCs are T cells, which through 
production of proinflammatory cytokines: TNF-α, IFN-γ, IL-17A, IL-17F, and IL-22 
induce the skin alterations that are observed in psoriasis20. 
 
1.3.2.1	  Dendritic	  cells	  
DCs are the sentinels of the innate immune system that bridge the innate and the 
adaptive immune systems. These cells are called professional antigen presenting cells 
that prime and polarize T cells to carry out antigen specific responses159. Langerhans 
cells and dDCs reside in the skin and therefore are well located to initiate 
inflammation in the skin in psoriasis123. At the same time pDCs are also thought to be 
highly involved in the psoriatic plaque formation76,160. 
 
1.3.2.1.1	  Langerhans	  cells	  
Langerhans cells are epidermal resident specialized DCs, which were the first subset 
of DCs found to express langerin (CD207)161. Under normal conditions they are 
located within the basal and suprabasal regions of the epidermis in the immature state 
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and are closely associated with keratinocytes through their expression of E-
cadherin162. Despite their epidermal localization the role of these cells in psoriasis still 
remains unclear20. 
 
1.3.2.1.2	  Dermal	  dendritic	  cells	  
dDCs are much less studied than Langerhans cells due to the difficulty of isolating 
these cells. In mice, dDCs contain at least one additional population that, similarly to 
Langerhans cells, express langerin163. The classical langerin- dDCs comprise the 
majority of the dermal DC pool and express integrin CD11b. The recently identified 
langerin+ dDC population represents 20% of the total dermal DC pool. Unlike 
Langerhans cells, langerin+ dDCs express the integrin CD103164. For simplicity, the 
two dermal-resident DC populations are called CD103+ DCs and CD11b+ DCs.  
Activated dDCs orchestrate the immune responses in the skin by secreting cytokines 
and chemokines to generate a cytokine milieu to effectively combat the insult. Most 
of the time this is beneficial and promotes the eradication of pathogens, but in rare 
cases it underlies a pathological tissue response with persistent inflammation. 
Activated dDCs produce both TNFα and inducible nitric oxide synthase (iNOS) are 
known as TIP (TNFα and iNOS-producing) DCs161,165. This type of DC has been 
proposed to have a major role in psoriasis through production of NO, resulting in 
vasodilation165,166. 
 
1.3.2.1.3	  Plasmacytoid	  dendritic	  cells	  
pDCs are a rare population of DCs that are most well-known for their specialized anti-
viral immune responses through production of type I IFNs160,167. They express high 
levels of TLR7 and TLR9 within their endosomes. The former recognizes single-
stranded RNA and small-molecule immune response modifiers such as Imiquimod, 
resiquimod and gardiquimod (imidazoquinolines)168,169. There have been many 
clinical observations of 5% Imiquimod cream Aldara™ (3M) exacerbating or causing 
relapses of psoriasis170-174. Elevated levels of type I IFNs72,175 as well as pDC numbers 
have also been reported in psoriasis170,176. These cells are not normally observed in the 
healthy skin, but have been found in both lesional and non-lesional psoriatic skin76. It 
is believed that pDCs are recruited to the skin by a fibroblast-derived molecule called 
chimerin. This molecule is abundantly expressed in prepsoriatic skin, adjacent to, and 
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within psoriatic plaques and is thought to promote the migration of pDCs from high 
endothelial venules to the skin177. In the xenotransplantation mouse model of psoriasis 
it was established that IFN-α produced by pDCs promoted activation and expansion 
of pathogenic T cells, leading to the development of psoriatic lesions. At the same 
time blocking IFN-α prevented T cell activation and lesion formation76.  
Under normal conditions pDCs are tolerant to self-DNA and -RNA, which arise from 
stressed or dying cells. However, it was shown that when these nucleic acids are 
bound to cathelicidin LL-37, they can trigger pDC activation through TLR7117,178. 
This event is thought to initiate the pathogenic cascade in psoriasis, allowing cross-
talk between stressed or dying keratinocytes and pDCs and through the action of type 
I IFNs promotes maturation and activation of dDCs and mDCs123. 
 
1.3.2.1.4	  Myeloid	  dendritic	  cells	  
Large numbers of mDCs have been found in psoriatic lesions, implying them in the 
disease pathogenesis116. Initial studies have shown that mDCs from psoriatic lesions 
mediate T cells responses, resulting in high levels of IL-2 and IFN-γ production. This 
lead to the initial belief that psoriasis is a TH1-type disease41,116,179,180. 
The numbers of mDC in psoriatic dermis compared to uninvolved skin have been 
reported to be increased up to 30 fold181. In psoriasis, mDCs are believed to be 
activated by proinflammatory cytokines secreted by pDCs, such as type I IFNs and 
IL-6, as well as TNFα produced by keratinocytes20. More recently, it was also 
postulated that mDCs can be directly activated by LL-37-self-RNA complexes 
through TLR8, leading to amplification of TNFα and IL-6 production178. 
There is yet no clear understanding and differentiation between dDCs and mDCs in 
psoriatic skin. But it is thought that mDCs also contribute to psoriasis through IL-
20182  and IL-23 production181,183. TNF induces ICAM-1 expression by keratinocytes 
as well as other proinflammatory cytokines, such as IL-6 and IL-1 and chemokines: 
IL-8, CCL2020. IL-20 can directly act on keratinocytes and induce their 
proliferation184. Moreover, with the recent shift in the understanding of the psoriasis 
pathogenesis, IL-23, for which DCs are the main source, induces polarization of T 
cells towards a TH17 phenotype183,185,186. Finally, it was recently suggested that 
fibroblasts can augment production of IL-23 by DCs through prostaglandin 2187. 
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1.3.2.2	  Macrophages	  
Macrophages can also act as APCs, even though they are not as efficient as DCs188, 
they are thought to be involved in psoriasis through TNF production189. Some 
macrophages also reside in the dermis and under inflammatory conditions migrate to 
the lymph nodes190. Additionally, their role in psoriasis may be due to their abilities to 
efficiently phagocytose tattoo particles and to regulate angiogenesis191,192.  
 
1.3.2.3	  T	  cells	  
The initial response to the stimulus results in the release of cytokines, chemokines and 
growth factors by keratinocytes and DCs. Following this it is believed that activated 
lymphocytes, which have been primed by the DCs in the lymph nodes and have 
upregulated skin homing receptors, extravasate into the dermis through increased 
vascularization and adhesion molecule upregulation. Under normal conditions more 
CD4+ TH cells reside in the dermis than in circulation193. At the same time epidermal 
lymphocytes are very rarely observed and the majority of these are CD8+ T cells123. 
In the lesional psoriatic skin activated memory T cells are primarily CD4+ TH cells in 
the dermis, and CD8+ T cells in the epidermis145,179,194. These findings and successful 
treatment of psoriasis patients with anti-T cell therapies have shifted the paradigm of 
keratinocytes being the main cellular players in psoriasis in favour of T cells195-199. 
These findings were further supported by the findings during allogeneic bone marrow 
transplantation200,201, indicating that psoriasis can be transferred through 
hematopoietic cells. Further reinforcement of this theory was provided by the studies 
in the mouse models of psoriasis (discussed later)202-205. 
Until recently, only TH1 and TH2 phenotypes of T helper cells were known. Psoriasis 
was considered to be a TH1 disease, while atopic dermatitis was classified as TH2 
disease206,207. However, with the recent discovery of so-called TH17 cells17,20,208,209 
and other differentially skewed phenotypes of T helper cells210-213 this belief initially 
turned into a duality (TH1/TH17)16,84,85 and even more recently into a triumvirate 
(TH1/TH17/TH22)86 (Figure 4)20. There are variable beliefs about T helper cell 
flexibility214 within the psoriasis and immunological field in general16,20,215. Therefore, 
it still remains to be determined, which cytokine producing profile is more important 
or if differential polarization of T helper cells occurs during different stages of the 
disease. 
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1.3.2.3.1	  Regulatory	  T	  cells	  
Treg cells are specialized T helper cell subset that represents 1-5% of peripheral CD4+ 
T cells. They are important for suppression of self-reactive T cells, self-tolerance and 
are characterized by expression of the transcription factor forkhead box protein 3 
(Foxp3), as well as high levels of CD25 and CTLA-4216-218. Their exact role in 
psoriasis is yet to be fully elucidated219 as in some studies these cells seem to be 
dysfunctional220 and in others they do not seem to be affected in psoriasis221. 
 
 
1.3.3	  Cytokine	  axes	  
As mentioned above cytokines such as TNFα, IFN-γ, IL-23, IL-17A, IL-17F, and IL-
Figure 4. Effector subsets of T helper cells and their roles in psoriasis. TH1cells 
differentiate in the presence of IL-12, IL-18 and IFN-γand produce IFN-γ. This, in turn, 
facilitates macrophage-mediated immunity against intracellular bacteria, protozoa, and 
viruses. TH2 cells develop in the presence of IL-4 and release IL-4, IL-5, IL-13, and IL-25. 
TH2 cells are important for cellular immunity against parasites and helminths mediated by 
basophils, eosinophils, and mast cells, as well as components of humoral immunity. TH17 
cells require a combination of TGF-β and proinflammatory cytokines (IL-1β, IL-6, IL-21, 
and IL-23) to differentiate. They produce IL-17A, IL-17F, and IL-22 and are important in 
neutrophil-mediated protection against extracellular bacteria and fungi as well as in 
keratinocyte production of antimicrobial peptides. Recently identified TH22 cells 
differentiate in the presence of TNF and IL-6 and produce IL-22. IL-22 acts on epithelial 
cells, for instance, keratinocytes, which proliferate and increase their production of 
antimicrobial peptides. Adapted from Perera et.al.,2012. 
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22 seem to play a crucial role in psoriasis. There are two distinct axes that are 
recognized in the context of psoriasis, the older IFN-γ/TNF-α and the newer IL-
23/TH17 axes. 
 
1.3.3.1	  IFN-­‐γ/TNF-­‐α	  cytokine	  axis	  
IFN-γ was long considered to be the main cytokine in psoriasis pathogenesis and 
despite the emergence of the IL-23/IL-17 axis, it still remains a strong favourite20. It is 
the principal TH1 cytokine and belongs to the family of type II IFNs222. The main 
producers of this cytokine are activated TH1 cells, NK and NK T cells, as well as 
CD8+ T cells. Supernatants from CD4+ T cell clones from psoriatic skin produce high 
levels of IFN-γ and GM-CSF223. Microarray studies have further underlined the 
importance of IFN-γ in psoriasis, showing its upregulation in psoriatic lesions, 
compared to healthy skin, as well as differential regulation of IFN-related genes224. In 
the same study transcription factor signaling alterations were the most consistent for 
STAT-1 and p48 (IFN-stimulated factor 3γ, both of which are induced by IFN-γ 
signaling pathway20. Interestingly, IFN-γ is known to have an antiproliferative effect 
on keratinocytes, but it was later explained by the fact that psoriatic keratinocytes 
have reduced activation of IRF1 and STAT-1 in response to IFN-γ225. At the same 
time IFN-γ upregulates adhesion molecules, chemokines, promotes further 
recruitment of lymphocytes, and stimulates DCs to produce IL-1 and IL-2320. 
TNFα has been historically grouped with IFN-γ, even though it is produced by many 
cell types including mast cells, macrophages, TH17 and TH22 cells226-228. There are 
two types of TNF, membrane bound and soluble versions. Both of these are 
biologically active and can bind either TNFR1 or TNFR2. The former is expressed on 
nearly all cells, while the latter is primarily found on endothelial and hematopoietic 
cells229-231. TNFR signaling can lead to NF-κB activation, resulting in 
proinflammatory signaling. Alternatively,  the mitogen-activated protein kinase 
(MAPK) pathway is activated, leading to cellular differentiation, proliferation, or 
apoptosis232,233. Due to its complex proinflammatory effects on cells it is 
understandable why targeting TNF in autoimmune diseases such as psoriasis plays a 
beneficial role, but at the same time this could lead to a variety of side-effects16,166. 
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1.3.3.2	  The	  IL-­‐23/IL-­‐17	  axis	  
In recent years IL-23 has been implicated as the major pathogenic cytokine in a 
variety of autoimmune diseases89,95,234-238. It is upregulated in psoriatic lesions183 and 
has been shown to be downregulated following systemic anti-psoriatic therapy166,239. 
Moreover, increased number of TH cells expressing higher levels of IL-23R have been 
found in the psoriatic lesions and general circulation of psoriasis patients238. The role 
of IL-23 in the pathogenesis of psoriasis has been underlined many times in different 
mouse models as well as in clinical trials, both of which will be described later on. 
IL-23 is critical for differentiation240,241 and production of IL-17 and IL-22 by TH17242 
and other cells types243. However, at steady state IL-23R is rarely expressed by naïve 
TH cells244, but at the same time is thought to favour terminal differentiation of TH17 
cells, their maintenance and pathogenicity245. In humans TH17 cells are quite 
heterogeneous and can also produce non-TH17 cytokines such as IFN-γ246,247.  
There are numerous reports of IL-17-producing cells in psoriatic lesions20,84,248,249, 
with increased levels of TH17 cytokines in psoriatic, compared to non-lesional skin250. 
The role of TH17 cells in psoriasis is further reinforced by the report of finding higher 
levels of these cells in the blood of psoriasis patients86. At the same time this was not 
the case for the serum of the patients251-253. There are also some studies that found 
CD8+ and NK T cells producing IL-17 in the psoriatic skin254,255. 
The IL-17 family of cytokines is comprised of six members IL-17A-F256,257. At the 
same time their receptor family contains 5 receptor subunits IL-17RA-E20,258. Only 
IL-17A, C and F have been reported to play variable roles in psoriasis259-261. IL-17A 
and F signal through IL-17RA and the RC heterodimeric receptor, while IL-17C uses 
the IL-17RE subunit instead of RC262,263. These receptors are mainly expressed on 
macrophages, neutrophils and epithelial cells, such as keratinocytes264-266. IL-17A and 
IL-17F signaling can mobilize, recruit and activate neutrophils, which are very 
abundant within psoriatic plaques267. Moreover, IL-17A/F signaling in keratinocytes 
results in production of IL-6, antimicrobial peptides and chemokines, including CCR6 
ligand CCL20265,266,268,269.  
IL-22 is another signature TH17 cytokine, which is important for epithelial tissue 
homeostasis270. It is a member of the IL-10 cytokine family. IL-22 shares IL-10R 
subunit and has its own unique subunit IL-22RA1 for signaling.  The unique subunit 
is expressed only by non-immune cells271. IL-22 signaling can also result in 
proinflammatory signaling and depends on target tissue as well as other cytokines272-
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274. Its role has been implicated in wound healing and tissue repair, but also in 
inflammation and infection184,270. In addition, IL-22 has synergistic effect with IL-17 
in inducing production of antimicrobial peptides by keratinocytes, which are 
upregulated in psoriasis275. Increased levels of IL-22 mRNA have been found in 
psoriatic skin and in the sera of the patients, while after successful treatment of 
psoriasis its levels normalized270. Accordingly, acanthosis observed in psoriatic 
plaques is mainly attributed to IL-22 proliferative effect on keratinocytes276.  
Originally, TH17 cells were thought to be the main producers of IL-22, but multiple 
studies were able to show that they account for less than 50% of IL-22 levels in 
psoriatic skin277,278. Moreover, IL-22 seems to have its own specialized transcription 
factor called aryl hydrocarbon receptor (AhR) 279, while TH17 cells are mainly driven 
by receptor‑related orphan receptor‑γt (Rorγt)209. At the same time it is still a matter 
of open debate whether TH22 cells represent distinct subset of T helper cells226. There 
have also been reports of CD8+ cells producing IL-22 in psoriatic lesions280. The 
complex pathogenic cascade implicated in the pathogenesis of psoriasis that have 
been described so far is summarized in Figure 5281. 
 
1.3.4	  Molecular	  mimicry	  theory	  
Despite psoriasis being considered an autoimmune disease no self-antigen has been 
identified to date. As described above the proposed mechanism of the disease 
initiation involves a complex interplay between a genetically susceptible individual 
and a variety of associated triggers, including infections, trauma, obesity, smoking, 
alcohol, medications, and anti-cytokine treatments for other non-related conditions20. 
But as with the majority of correlative findings it is hard to prove or disprove their 
real contributions. Recently, the LL-37-self-DNA, -RNA complexes were found to be 
a probable trigger for psoriasis117. However, this does not identify an antigen, which is 
recognised by the pathogenic T cells that are found in psoriatic lesions. One of the 
most prominent, well studied and accepted theories is the molecular mimicry theory, 
which implicates the homology between the streptococcal M protein and keratins 14, 
16 and 17 to be the driving factor in the psoriasis pathogenesis282. 
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1.3.4.1	  Streptococcal	  infections	  and	  palatine	  tonsils	  
Correlation between streptococcal throat infection and the acute guttate form of 
psoriasis (an early onset form) has been documented in many studies. The incidence 
of streptococcal infections preceding this type of psoriasis ranges from 56% to 
97%283. Moreover, chronic plaque psoriasis is generally exacerbated after 
streptococcal infections. Interestingly, these observations are consistent only with the 
three groups of β-hemolytic streptococci (A, C and G), all three of which express M-
protein on their surface110. M-protein is a major virulence factor comprised of two 
polypeptide chains. It has a very variable N-terminal part, but highly conserved 
Figure 5.  Initiation, acute, and chronic stages of psoriasis. pDCs produce IFN-α after 
being triggered by LL-37/self-DNA complexes, inducing maturation and differentiation of 
skin resident DCs. Inflammatory DCs and mDCs produce TNFα, iNOS, and IL-23, which 
induce TH1 and TH17 cell responses. The TH1 cytokine IFN-γ induces keratinocytes to 
produce proinflammatory chemokines and increase production of vascular endothelial 
growth factor, promoting angiogenesis. IL-23 stimulates TH17 and TH22 cell 
differentiation and production of IL-17 and IL-22. IL-17 induces keratinocytes to produce 
chemoattractants for T cells, neutrophils, and mononuclear cells. IL-22 promotes 
epidermal acanthosis. IL-17 and IL-22 induce keratinocyte production of antimicrobial 
peptides, resulting in a self-amplifying inflammatory loop by inducing more LL-37/self-
DNA complexes. Adapted from Guttman-Yassky et.al.,2011 
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membrane-anchored C-terminal, even within different bacterial strains and 
serotypes42. No association has been found between psoriasis and particular M 
serotypes. At the same time non-symptomatic carriage of streptococcus in the tonsil 
crypts is common. 
 
1.3.3.2	  Oligoclonality	  of	  lesional	  T	  cells	  in	  psoriasis	  
Numerous studies have reported chronic psoriasis lesions infiltrated by oligoclonal T 
cells282. Some follow-up studies show that dominant T cells clones persist in 
circulation for a long time, but reappear in psoriatic skin after drug-induced 
remission284-287. Moreover, identical clones have been identified in the psoriatic skin 
and synovial lesions of patients with psoriatic arthritis288,289. 
Recently, T cell clones, which expand in the palatine tonsils, were implicated in 
maintaining psoriatic lesions290. Accordingly, a number of patients with a history of 
moderate to severe plaque psoriasis all experienced at least 3 years remission after 
tonsillectomy. Interestingly, in all of them highly restricted T cell receptor (TCR) Vβ 
spectratypes of lesional T cells were found. Additionally, sequencing of the CDR3 of 
the TCR Vβ-chain found a number of identical clonal rearrangements within the 
lesional skin of all the patients290.  Some of the identified clones were also found in 
the tonsils of these patients and were cutaneous lymphocyte antigen (CLA) positive, 
indicating the tonsils as a potential site for the expansion of the pathogenic T cell 
clones282. 
 
1.3.3.3	  Cross-­‐reactive	  T	  cells	  in	  psoriasis	  patients	  
Of more than 4000 mammalian proteins, human type 1 keratins have the highest 
homology with the streptococcal M6 protein291. This led to the theory that psoriasis is 
initiated by streptococcal superantigens and the disease is maintained by T cell clones 
that are cross-reactive for streptococcal M protein in the tonsils and keratins in the 
skin292. Further studies of the occurrence of circulating T cells that would be triggered 
by short homologous M and K peptides found much higher frequency of these cells in 
the psoriasis patients compared to controls293,294. Moreover, strong predisposition for 
psoriasis in carriers of the HLA-Cw*0602 allele was utilized to study sets of 
homologous peptides from K17 and M proteins, which were also predicted to bind to 
HLA-Cw6. The HLA-Cw6 negative psoriatic patients had T cell responses to both 
  Introduction 
 
 37 
sets of peptides that were intermediate between those of the HLA-Cw6 positive 
patients and the controls. At the same time the majority of the responding cells were 
also positive for CLA295. Collectively these findings and the recent extensive study on 
remissions in psoriasis patients after tonsillectomy296 make the cross-reactivity theory 
quite attractive and is most applicable to the group of early onset psoriasis 
patients20,297. 
  
1.4	  Anti-­‐psoriatic	  therapies	  
Even though the pathogenesis of psoriasis is not completely understood, some very 
effective and by now quite sophisticated therapies are available. These range from 
topical treatments for limited disease, to anti-biologics, which are used in cases of 
mild to severe psoriasis. Things that should be taken into account when prescribing 
the most efficient therapy are anatomical location, treatment history, exacerbating and 
favourable factors, quality of life concerns, etc298. 
 
1.4.1	  Topical	  therapies	  
This type of therapy remains the most common type of psoriasis treatment and is 
generally used as monotherapy. It is primarily prescribed to patients with limited 
disease. Despite being effective for individual plaques, it is time consuming, and 
compliance with the treatment schedule is the greatest issue.  
Topical corticosteroids are the most widely prescribed treatment for psoriasis 
worldwide. Depending on the potency of the agent, they can provide rapid efficacy, 
cosmetic acceptability, and are quite versatile. The Stoughton-Cornell classification is 
used to grade potency, and thus the relative effectiveness of corticosteroids on the 
basis of their ability to induce vasoconstriction299.  It is proven that potent and very 
potent topical steroids are more efficacious for psoriasis treatment than the ones with 
mild or moderate potency300. The safety of long-term corticosteroid use is not yet 
defined. In one study, a 1-day per week corticosteroid application led to clinical 
response in 60% of patients, compared with 20% placebo controls, and was safe for 
up to 6 months301.  
Vitamin D3 derivatives have recently become the first-line therapy for plaque 
psoriasis. They can be used either as a monotherapy or in combination with other 
treatments. The clinical responses to these are slower than with higher potency 
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corticosteroids, but their longer-term safety profile makes them valuable for 
maintenance therapy302. These analogues are very valuable in combination therapy, as 
they allow for a reduction in the dose and duration of other antipsoriatic agents303.  
Tazarotene is currently the only topical retinoid (vitamin A derivative) for the 
treatment of psoriasis. It has only moderate efficacy as monotherapy304 and thus is 
mainly used in combination therapies305. In addition, it often causes skin irritation and 
cannot be used during pregnancy and it is advisable to limit its use in women of 
childbearing age. 
Topical calcineurin inhibitors unlike corticosteroids do not cause skin atrophy, but 
their efficacy is quite low306, unless specifically used on the thinner skin of the face, 
intertriginous areas, or genitals307.  
Dithranol was the main treatment for psoriasis for over 80 years, but its use has been 
declining steadily due to emergence of more cosmetically acceptable drugs. 
Additionally, it has lower efficacy than either topical corticosteroids or vitamin D₃ 
derivatives300. 
Coal tar, which is a mixture of many compounds, has been used in the treatment of 
psoriasis for over a century. Crude coal tar is the most effective form available and is 
slightly less efficacious than corticosteroids. Skin irritation, folliculitis, odour, and 
staining of clothing, and oncogenic potential limit its use308.  
	  
1.4.2	  PUVA	  photochemotherapy	  
PUVA photochemotherapy is the combination of an ingested psoralen photosensitiser 
and exposure to UVA. It is a very efficacious treatment for psoriasis, with a long 
lasting remission. But there are many undesirable side effects to this treatment, 
including nausea and headache from the ingested psoralen as well as skin burning, 
and photosensitivity. Premature cutaneous ageing, an increased risk of non-melanoma 
skin cancers, and possibly melanomas, are of particularly high concern309,310. After the 
introduction of narrowband UVB, the use of PUVA has substantially decreased 
worldwide. 
 
1.4.3	  Narrowband	  UVB	  
Natural sunlight is an effective treatment for psoriasis. The most effective wavelength 
is 311–313 nm (narrowband UVB) range311. Currently, narrowband (NB) or wideband 
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UVB is primarily used together with combinations of tazarotene, vitamin D3 
analogues, or systemic treatments312. NB-UVB suppressed multiple parameters of the 
IL-23/IL-17 pathway in normalized psoriatic plaques, but not in nonresponsive 
plaques. Very recently, it was shown that narrowband UVB treatment decreases the 
numbers of TIP DCs, and their products, including inducible nitric oxide synthase 
(iNOS), IL-12/23p40, and IL-23p19. Moreover, during successful treatments NB-
UVB suppressed IL-17 and IL-22 mRNAs, which strongly correlated with lesion 
resolution. Therefore, in addition to its known role in suppressing IFN-γ production, 
NB-UVB radiation therapy can also target the IL-17 pathway to resolve psoriatic 
inflammation313. 
 
1.4.4	  Systemic	  non-­‐biological	  treatments	  
Systemic treatments are primarily used for patients with moderate to severe disease 
and the ones that are unresponsive to topical agents or phototherapy. Issues that 
should be taken into consideration before prescribing such treatments include HIV 
status, presence of hepatitis, and previous systemic cancers.  Most recently biological 
therapies provide new options for patients who previously were intolerant of or 
unresponsive to traditional systemic agents298. 
 
1.4.4.1	  Retinoids	  
Oral retinoids are synthetic hormones that bind to nuclear retinoid receptors. By doing 
this they alter gene transcription in keratinocytes and possibly T cells, resulting in 
remission of psoriasis. Systemic retinoids are especially effective for the treatment of 
erythrodermic and pustular variants of psoriasis314. But as with many of anti-psoriatic 
drugs systemic retinoids should not be given to women considering pregnancy. It has 
recently been demonstrated that all-trans retinoic acid (ATRA) can suppress TH17 
cell differentiation and promote the generation of Foxp3+ regulatory T cells via 
retinoic acid receptor signals315. 
 
1.4.4.2	  Ciclosporin	  
Ciclosporin can be used as short-term treatment for moderate-to-severe psoriasis. It 
inhibits the calcineurin phosphatase-initiated activation of T cells316 and may also 
exert a direct effect on keratinocytes317. Ciclosporin is extremely effective in inducing 
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rapid remission of psoriasis. Unlike methotrexate, ciclosporin is not teratogenic or 
myelosuppressive318, but still requires very careful monitoring due to potential 
nephrotoxicity and hypertension319,320. 
 
1.4.4.3	  Methotrexate	  
Methotrexate is a folic acid antagonist. It interferes with purine syntheses, which 
inhibits DNA synthesis and thus cell replication. Moreover, it has specific T cell 
suppressive activity. Even though newer and more sophisticated therapies are 
available by now, methotrexate continues to be affordable, gold standard treatment for 
recalcitrant psoriasis and psoriatic arthritis. Unfortunately, methotrexate has some 
severe side effects. Its use is completely out of question during pregnancy. Bone 
marrow suppression is the most common cause of death attributable to this treatment. 
During direct comparison between ciclosporin and methotrexate in treatment of 
psoriasis no significant differences in efficacy, time to remission, rates of remission, 
and quality of life improvements were observed321. 
 
1.4.4.4	  Fumaric	  acid	  esters	  
Fumarates are naturally occurring compounds that can link the urea and citric acid 
cycles. Their benefits in psoriasis treatment are now considered to be mainly due to 
NF-κB inhibition and T-cell apoptosis322. Psoriasis Area and Severity Index (PASI) 
reductions associated with fumarates are similar to those of methotrexate and 
ciclosporin323,324. Despite absence of severe adverse events, the fumarates can cause 
highly unpleasant gastrointestinal symptoms and fatigue325. 
 
1.4.5	  Biologicals	  
Better understanding of the immune pathways involved in the pathogenesis of 
psoriasis has led to the development of new agents that specifically target them. The 
coincidental alleviation of psoriasis that occurred during the treatment of other 
inflammatory diseases identified the involvement of T cells in psoriasis. This resulted 
in the development of anti–T cell therapies. Most recently, greater appreciation of the 
molecules involved in the pathogenesis of psoriasis resulted in cytokines and their 
receptors being targeted. As with all therapies these days, advancing technological 
platforms and the availability of high-throughput sequencing will hopefully allow 
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personalized immunogenetic therapies. The eventual goal of this would be to predict 
individual prognosis and therapeutic response with minimal side effects. 
	  
1.4.5.1	  Anti-­‐T	  cell	  biological	  therapies	  
Alefacept was the first biological agent approved for the treatment of psoriasis. It is a 
human recombinant protein that binds to CD2 on memory effector T cells, selectively 
interfering with the function of APCs and thus, T-cell activation326. It also causes 
apoptosis of memory-effector CD45RO+ T cells in the skin327.  Treatment with 
Alefacept resulted in 20% of patients achieving a 75% reduction in PASI (PASI 75) 
after 12 weekly intramuscular injections and had hardly any associated side-effects328. 
Efalizumab is a humanized monoclonal antibody, which binds CD11a and inhibits 
activation of T cells, as well as their adhesion to endothelial cells, thus preventing 
circulating T cells from entering the skin329. Efalizumab is slightly more efficacious 
than Alefacept and substantially improved psoriasis in patients with moderate-to-
severe disease. About 25% of patients achieved PASI 75 by 12 weeks for periods of 
up to 15 months. The maximum response (47% PASI 75) was observed after about 24 
weeks of treatment without substantial side effects330-332. Unfortunately, Efalizumab 
was recently withdrawn from the European and American markets after five years of 
use due to three cases of progressive multifocal leukoencephalopathy333. 
 
1.4.5.2	  Anti-­‐TNF	  therapies	  
Etanercept is a human recombinant TNF receptor p75 protein that binds to TNFα and 
β. It can be self-administered subcutaneously, with 34% of patients achieving PASI 
75 by 12 weeks. Higher doses of 50 mg twice weekly, as approved in the USA, for up 
to 12 weeks of initial therapy, resulted in 49% of patients achieving PASI 75334. Very 
importantly, etanercept also relieves fatigue and symptoms of depression in patients 
with moderate-to-severe psoriasis. Moreover, Etanercept is also highly efficacious for 
psoriatic arthritis treatment, with a reduction in the signs and symptoms of joint 
disease in 73–87% of patients after 12 weeks of treatment335. Interestingly, effective 
treatment of psoriasis with etanercept was recently linked to suppression of IL-17 
signaling rather than immediate response TNF genes336,337. 
Infliximab is a chimeric monoclonal antibody, which neutralises the activity of TNFα. 
It is more efficacious than etanercept with 82% of patients achieving PASI 75 after 10 
Introduction   
 
 42 
weeks of treatment338. Infliximab is also quite effective for treatment of psoriatic 
arthritis339. 
Adalimumab is a fully human, anti-TNFα monoclonal antibody. Its efficacy is in-
between etanercept and infliximab with 54% of patients achieving PASI 75 after 24 
weeks340. As with the other two anti-TNF therapies it also has positive impact on 
psoriatic arthritis341. 
 
1.4.5.3	  Anti-­‐IL-­‐12/23p40	  therapies	  
Ustekinumab is a human IgG1 monoclonal antibody, which binds to the p40 subunit 
of IL-12 and IL-23 and prevent its interaction with IL-12Rβ1342 (see Figure 3). It was 
shown to be more efficacious than etanercept, with improvement to PASI 75 at week 
12 in 67.5% of patients who received a low dose of ustekinumab and 73.8% of 
patients who received a higher dose, compared with 56.8% of those who received 
etanercept343. 
Briakinumab is a similar monoclonal antibody, which seems slightly more efficacious 
than ustekinumab with 80.7% of patients achieving PASI 75 at week 12344. However, 
currently only ustekinumab is approved for treatment of psoriasis. 
 
1.4.5.4	  Anti-­‐IL-­‐17	  therapies	  
Currently no anti-IL-17 therapies are approved for treatment of psoriasis. However, 
recent clinical trials of three drugs targeting IL-17 have shown great promise. 
Secukinumab is a human monoclonal antibody against IL-17A345. Ixekizumab is a 
humanized monoclonal antibody against IL-17A346. Brodalumab is a human anti–IL-
17RA monoclonal antibody347. Interestingly, these antibodies have shown quite 
variable results in clinical trials. Ixekizumab has proven to be the most efficacious 
with 82% of patients achieving PASI 75346. At the same time this was significantly 
lower for Secukinumab (40%)345 and Brodalumab (45%)347. These results have at 
least two possible explanations. In case of Ixekizumab it seems that the efficacy of 
ustekinumab is purely due to blocking IL-23 and thus shows that the IL-23/TH17 axis 
is a lot more important in psoriasis than IFN-γ axis. At the same time, the results for 
Secukinumab would imply a synergistic role of IL-17 and IFN-γ axes. Finally, the 
results for Brodalumab suggest the same as Secukinmab, but it is known that IL-17A, 
C, E and F signal through IL-17RA256, which complicates the interpretation of these 
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results. However, Ixekinzumab results show great promise and prove that due to our 
better understanding of the pathogenesis of psoriasis more efficacious and specific 
therapies are being developed. 
 
1.5	  Models	  of	  psoriasis	  
With the exception of a few rare cases in primates, psoriasis is unique to humans. 
Therefore a big part of the described mechanism of psoriasis pathogenesis (Figure 5) 
would not have been possible without preclinical model systems The available models 
of psoriasis generally provide only an approximation of the disease16,202-205,348,349. The 
four main types of in vivo animal models nearly exclusively rely on mice, with 
variable experimental settings: spontaneous mutation, genetic engineering, 
xenotransplantation and cytokine injection models. However, major differences are 
quite apparent between human and mouse skin, making the results of the model 
studies less conclusive. Firstly, the human skin is thicker in comparison with that of 
mice. Secondly, mice have much higher average hair distribution density. Mice do not 
have sweat glands and melanocytes in the interfollicular epidermis, but have more 
rapid epidermal turnover and the presence of a unique epidermal subset of γδ T 
cells350 (Figure 6)205.  
 
1.5.1	  Spontaneous	  models	  
There are some mouse strains that develop spontaneous skin diseases, which are 
macroscopically reminiscent of psoriasis. Chronic proliferative dermatitis disease is 
observed in mice with Sharpincpdm⁄Sharpincpdm allele mutation. These studies have 
shown increased rate of keratinocyte proliferation, but primarily granulocytes and 
only a small fraction of T cells comprised the skin infiltrating leukocytes. However, in 
this model, immune cells infiltrates were also observed in some joints. At the same 
time the disease could not be transferred by bone marrow or spleen transplants. 
Treatment of these mice with corticosteroids, resulted in nearly complete regression 
of the lesions, but this was not the case for systemic cyclosporine treatment351. 
The flaky skin mutation (Ttc7fsn⁄Ttc7fsn) mice displayed a marked dermal infiltration 
of lymphocytes and mast cells, together with a small increase in the number of 
granulocytes. Some angiogenesis, as well as progressive papillomatosis were also 
observed in this model352. Another spontaneous psoriasis-like mouse strain is 
Introduction   
 
 44 
homozygous for the mutated asebia allele (Scd1ab⁄Scd1ab) 353. Overall, these models 
have many features reminiscent of psoriasis, but they lack T-cell infiltrates, 
characteristic of psoriatic lesions and their responses to treatment with antipsoriatic 
drugs are low205,354. 
 
 
 
 
1.5.2	  Genetically	  engineered	  mouse	  models	  
There are two broad types of genetically engineered mouse models of psoriasis: mice 
that had a genetic element introduced (transgenic mice), and the ones in which a 
genetic element had been removed (gene knock-out mice). These models are very 
good for determining if overexpression of a given cytokine, growth factor, or 
adhesion molecule in isolation would have a role in skin inflammation16. Epidermal 
overproduction of molecules expressed under the control of promoters that act in the 
basal epidermal layer: keratin 5 (K5) and keratin 14 (K14), as well as proteins that 
function in the suprabasal epidermal layers, including involucrin and keratin 10 
(K10), induce the development of a psoriasis-like disease in several mouse models205. 
 
Figure 6. Schematic representation of human and mouse skin showing differences in 
stratification and the different cell types present. 
Adapted from Wagner et.al., 2010. 
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1.5.2.1	  Gene	  knock-­‐out	  models	  
As described above IL-1β is constitutively expressed in keratinocytes and its mRNA 
is increased in psoriatic lesions355. In line with this, mice with a targeted deletion of 
the IL-1 receptor antagonist gene also develop a psoriasis-like phenotype with 
epidermal hyperproliferation and an inflammatory infiltrate in the skin, as well as 
some joint inflammation356. 
The NF-κB pathway is important for transcription of IL-1 and many other 
proinflammatory genes (see above). Deletion of one of the subunits of the NF-κB 
inhibitor, IκB kinase IKK2, induced a strong psoriasis-like inflammation in the mouse 
skin. This inflammation was dependent on TNF with marked infiltration and 
activation of dermal macrophages. But at the same time these mice had developed 
features uncharacteristic for psoriasis, such as keratinocyte apoptosis and was T-cell-
independent357,358. 
The transcription factor AP-1 members have been shown to be expressed in human 
and mouse epidermis359. Skin specific deletion mouse models show quite conclusively 
that some of these are important regulators of skin inflammation360,361. Inducible 
epidermal deletion of JunB and c-Jun in adult mice leads to a chronic psoriasis-like 
disease, including joint involvement362. Moreover, these mice had increased 
production of IL-23 and TH17 cytokines. However, in the same model the severity of 
inflammation was reduced in mice crossed with the ones lacking either RAG1 or the 
TNFR1 genes, suggesting that cells other than T cells initiate the inflammation. At the 
same time, a therapeutic approach using an anti-VEGF antibody led to an 
improvement in skin inflammation363. 
	  
1.5.2.2	  Transgenic	  mouse	  models	  
STAT3 is crucial for the differentiation of TH17 cells. At the same time, it has 
importance for wound healing and skin carcinogenesis364,365. In the K5-STAT3C 
mouse model, skin inflammation reminiscent of psoriasis develops in a spontaneous 
fashion or can be triggered. It has features very similar to psoriasis, including loss of 
the stratum granulosum, dilated blood vessels and an immune infiltrate of 
lymphocytes and neutrophils364. 
As described above for the K5-JunB/c-Jun model, VEGF was important for the 
disease development and is also elevated in the skin and serum of patients49. 
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Accordingly, K14-VEGF transgenic mice develop psoriasis-like skin phenotype, with 
increased proliferation and abnormal differentiation of keratinocytes, and an immune 
infiltrate similar to psoriatic lesions366. 
Anti-TNF therapy is efficacious in psoriasis20,334. Accordingly K14-TNF mice have 
an immune infiltrate in the skin, but these also die of intestinal and liver necrosis367. 
Interestingly, peroxisome proliferator activator receptor β/δ (PPARβ/δ), which 
regulates keratinocyte differentiation, is a downstream target of TNF and has been 
implicated in psoriasis368. Suprabasal induction of PPARβ/δ caused a skin 
inflammation in mice, which was dependent on STAT3 phosphorylation, IL-
12/23p40, and TNF. It also simulates the features of psoriasis in relation to signaling 
pathways369. 
Finally, in line with IL-12/23p40 and TGF-β being important for differentiation of 
TH17 cells139,242, K5-TGF-β1 and K14-p40 models also closely resemble 
psoriasis370,371. 
 
1.5.3	  Transplantation	  models	  
Transplantation models are the most sophisticated models of psoriasis as they involve 
transferring the disease from mice or humans into mice. Therefore they duplicate the 
transfer of the disease as it has been described for the human disease200,201. Moreover, 
these models could be the best types of models to conduct preclinical tests of potential 
anti-psoriatic drugs. 
 
1.5.3.1	  Cell	  transplantation	  models	  
A disease with psoriasis features could be transferred into Prkdcscid mice with 
CD4+CD45RBhi T cells from donors that were MHC matched, but mismatched for 
minor histocompatibility antigens372. Additionally, RAG2-/- mice reconstituted with 
CD4+CD45RBhi T cells developed quite similar phenotype373. Both of these models 
support the notion that psoriasis-like skin lesions can be induced by T cells, but at the 
same time run into danger of mimicking graft vs. host disease instead. 
	  
1.5.3.2	  Xenotransplantation	  models	  
In this model the skin from psoriasis patients is transplanted onto immunosuppressed 
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mice. Interestingly, transplants can be from non-lesional or lesional skin. These can 
be employed to study either the development of psoriatic lesions or already 
established psoriasis. Therefore, they are well designed to understand the disease 
initiating pathways, as well as disease maintaining ones. The most recent model of 
this type uses AGR129 (RAG-/-, IFNRI-/-, IFNRII-/-) mice as hosts. This model has 
been invaluable for underlining the importance of T cells, TNF, pDCs, type I IFNs, 
α1β1 integrin and IL-23 in the pathogenesis of psoriasis76,238,374,375.  
 
1.5.4	  Other	  models	  
Despite marked success of the xenotransplantation model in advancing our 
understanding of psoriasis and development of anti-psoriatic therapies, not all of the 
findings in this model have been successfully translated into effective anti-psoriatic 
treatments. Most recently, this was underlined by failure of anti-IFN-α therapy in 
psoriasis trials376. This and other factors, such as limited availability of human skin 
grafts from psoriasis patients, cumbersome experimental procedure and a long time 
for the disease development have led to the development of new models. These were 
primarily aided by our increasing understanding of the disease pathways and clinical 
observations.  
This type of model utilizes our knowledge of the main molecular players in psoriasis 
pathogenesis. This is used to ‘shortcut’ the original stimulus for the disease initiation. 
Subcutaneous injections of Il-21, Il-23, and to a lesser extent Il-12, induce a psoriasis-
like disease in mice377-381. 
 
1.5.5	  Aldara	  model	  
The Aldara model is based on clinical observations that topical treatment with Aldara 
cream, for unrelated conditions, could trigger and cause relapses of psoriasis in 
patients170-174. The active ingredient of Aldara, Imiquimod is a ligand for TLR7, and a 
strong immune modifier. In clinics, it is used for topical treatment of genital and 
perianal warts, caused by human papilloma virus (HPV)382. Recently, the clinical 
applications were additionally expanded to other virus-associated skin abnormalities 
and cancerous skin lesions, such as actinic keratoses383 and superficial basal cell 
carcinomas384. Additionally, Aldara induced psoriatic lesions were found to contain 
pDCs, similar to that of lesions caused by other triggers170. Moreover, this model 
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satisfies most criteria for a good psoriasis model203, including: epidermal changes 
based on keratinocyte hyperproliferation and altered differentiation; papillomatosis; 
presence of inflammatory cells, including T cells, DC, and neutrophils; a functional 
role for T cells; and altered vascularisation385. The only criterion that was not been 
tested in this model was response to the well-established antipsoriatic drugs. It was 
also shown that the Aldara skin inflammation in mice is dependent on IL-23p19 and 
IL-17RA. What also makes this model very attractive is the quick development of the 
psoriasis-like lesions, within 4-5 days. On the other hand it implies innate immune 
mechanisms being pivotal for the development of Aldara driven skin inflammation. 
Finally, in the original study it was mentioned that higher percentage of IL-17A 
producing γδ T cells were detected in the in spleens of Aldara-treated mice compared 
with controls385. 
 
1.6	  Innate	  sources	  of	  IL-­‐17	  and	  IL-­‐22	  	  
Recent studies on the role of IL‑23 in autoimmunity unearthed a novel subset of T 
cells that are important for chronic inflammation and tissue damage139,208. This led to 
the quickly accepted TH17 cell paradigm, in which IL‑6–STAT3 activation pathway 
of the transcriptional regulator retinoic acid RORγt controls the lineage fate of 
IL‑17A‑, IL‑17F‑, IL‑21‑ and IL‑22‑producing T cells (known as TH17 cells)386. These 
are highly responsive to IL‑1 receptor 1 (IL‑1R1) and IL‑23R signaling209,387. But this 
cell lineage cannot explain the early IL‑17‑dependent responses, crucial during stress 
responses and host defense. It has been observed that the IL‑17‑mediated pathway is 
triggered within hours after epithelial cell injury or through PRRs388,389. This would 
clearly not provide enough time for the development of TH17 cells386. 
Further support of the innate sources of IL-17 and IL-22 is underlined by studies 
where these cytokines were induced in RAG-/- mice245,390,391. A closer look at 
evolution also reinforces the idea that IL-17 is an innate cytokine as ancestors of this 
gene-family are preserved among invertebrate species392. Finally, studies in IL-23R, 
RORγt, IL-17A and IL-17F reporter and fate-mapping mice clearly established that at 
least IL-17 is primarily produced by CD4 and CD8 negative T cells244,393-395.
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1.6.1 γδ T cells 
Together with B cells, αβ T cells, γδ T cells and NK T cells are the only cells that use 
somatic gene rearrangement to generate diverse antigen receptors. This cell type was 
simultaneously classified by two groups396,397 and other nomenclatures have been 
suggested as well398. Here the Heilig and Tonegawa nomenclature is used397. γδ T 
cells constitute only up to 5% of the circulating lymphocytes in most adult animals399. 
However, they are a lot more abundant in the epithelial tissues, such as the skin, 
intestine and reproductive tract, where they can make up to 50% of all T cells.	  In the 
thymus, γδ T cells develop from double-negative thymocytes and branches off from 
αβ T cells at the transition of thymocytes from the DN3 to the DN4 stage. Models of 
selective and instructive αβ vs. γδ lineage commitment have been postulated based on 
TCR signal strength400 or Notch signaling401. Current knowledge favours the signal 
strength hypothesis402,403. TCRγδ+ thymocytes are first ones to develop out of all T 
cells and can be found in the embryonic thymus starting from embryonic day 14. The 
waves of γδ T cell development start with Vγ5+Vδ1+ DETCs, followed by Vγ6+Vδ1+ 
progenitors that subsequently localize to the mucosal tissues. Thymic terminal 
transferase is not expressed during these prenatal stages, resulting in simple V-D-J 
joins that characterise the canonical TCRs of fetal-derived γδ cells398,403. On the other 
hand, postnatal gut and lymphoid γδ T cells acquire diverse V-D-J joins in their Vγ1, 
2, 4 and 7-containing TCRs403. This ordered progression of γδ T cell generation and 
tissue-specific localisation are partly due to ordered Vγ-region transcription and 
rearrangement and partly due to preTCR programming (Figure 7)399,403,404. 
Peripheral γδ T cells can recognize self and non‑self ligands, which divides them into 
antigen experienced and antigen naive groups, which produce IFNγ or IL‑17, 
respectively405. At the same time, this differentiation can also be made based on 
surface marker CD27 (TNFR family member), with CD27+ cells producing IFNγ and 
CD27- ones producing IL‑17406. Similar distinction is achieved by using markers such 
as CCR6, NK1.1 and SCART2407,408. Unlike naïve αβ T cells, certain subsets of γδ T 
cells are programmed for rapid responses to a variety of stimuli by expressing 
multiple PRRs (TLR1 and 2, dectin-1) through production of IL-17 and IL-22409.  
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At the same time IL-17-producing γδ T cells constitutively express IL-1R and IL-23R, 
triggering of which amplifies their production of cytokines410. Recently, γδ T cells 
were shown to be important for protection against a variety of pathogens, including 
Listeria, Streptococcus and Malaria411-413. Moreover, they have been implicated to 
play crucial roles in a variety of mouse models of autoimmunity410,414-417. Recently, 
IL-17-producing populations of γδ T cells have been found in the skin of mice418,419. 
Finally, there has been a report that the numbers of γδ T cells are increased in 
psoriatic lesions420. 
 
1.6.2 Innate lymphoid cells (ILCs) 
Very recently a new innate source of IL-17 and IL-22 was identified in form of innate 
lymphoid cells (ILCs)421. These develop from the same hematopoietic precursors as T 
Figure 7. Mouse γδ T-cell generation is developmentally programmed. γδ T cells are 
encoded by specific Vγ-gene segments (see graph) and migrate from the thymus at defined 
periods of fetal and neonatal development. Modified from Carding and Eding 2002. 
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lymphocytes, but do not express any specific antigen receptors422. One of the more 
well studied members of this family are the NK cells. NK cells are critical for the 
immune recognition of transformed or tumour cells as well as cells infected with 
viruses67. Another prominent member of this family are lymphoid tissue inducer (LTi) 
cells that are important for the development of the lymphatics423.    
All ILCs depend on transcription factor Id2 (inhibitor of DNA binding-2). ILCs do 
not express any known lineage markers, but are positive for IL-7 receptor α chain (IL-
7Ra; CD127) and the cytokine common gamma (γc) chain424. Originally, these cells 
were identified as a very minor population within the spleen, which were readily able 
to produce IL-17 and IL-22421. Moreover, they were found to constitutively express 
RORγt, AhR, CCR6 and IL-23R, strikingly resembling IL-17-producting γδ T 
cells88,421. The majority of studies have shown that IL-22-producing ILCs are 
particularly important in the intestinal homeostasis as well as protection against 
certain bacterial strains425, viruses426, and tumour rejection427. Importantly, their role 
was recently demonstrated in the models of colitis428-430. However due to their low 
abundance and lack of specific markers these cells are hard to study and are still quite 
poorly characterised. 
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1.7	  Aims	  of	  the	  study	  
The original study on Aldara psoriasis was primarily performed using Balb/c mice385. 
Therefore, the first objective would be to establish the Aldara mouse model of 
psoriasis in C57/B6 wild-type mice. Aldara cream is a kind of a ‘black box’. Thus, it 
would be important to understand if the inflammation observed in this model is purely 
dependent on the TLR7 agonistic activity of active ingredient of Aldara, 
Imiquimod431. pDCs are the cell type that expresses the highest levels of TLR7. 
Therefore, their role and the role of their effector cytokines type I IFNs need to be 
established in the initiation of the Aldara psoriasis. This model has been quite well 
characterized and shown to satisfy the majority of the criteria for a good psoriasis 
model203. The only criterion that has not been addressed was the responsiveness to 
conventional ant-psoriatic therapies, and therefore will be tested in this study.  
Moreover, in the original study only the dependence on IL-23p19 and IL-17RA were 
shown385. Thus, it would be interesting to establish the differential roles of so called 
TH17 cytokines IL-17A, IL-17F and IL-22, as well as transcription factor RORγt in 
the Aldara psoriasis model. As discussed above the Aldara induced skin inflammation 
develops very rapidly and therefore it would be of particular interest to study the 
effector cells that are crucial for the development of the disease. It seems quite 
unlikely that TH17 would be the only cell type to play an important role in the Aldara 
psoriasis and therefore the roles of γδ T cells and may be ILCs need to be 
investigated. Overall, better understanding of the disease initiating events in this 
model would help improve our understanding of the initiation phase of the 
pathogenesis of psoriasis. 
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2 Results 
2.1	  The	  Aldara	  psoriasis	  model	  characterisation	  
2.1.1	  Appearance	  of	  Aldara	  psoriasis	  
To initiate psoriasis-like inflammation, Aldara cream was applied to the shaved back 
and the ears of C57BL/6 mice for 6 consecutive days as previously described for 
BALB/c mice385. From day 3 onwards we observed significant thickening 
(acanthosis), reddening (erythema) and scaling (dysregulation of keratinocyte 
differentiation) of the portions of skin treated with Aldara, compared to the ones 
treated with control cream (Figure 8A). Overall, the macroscopic appearance of the 
disease replicated human psoriasis quite well.  
 
2.1.2	  Kinetics	  of	  Aldara	  psoriasis	  
Originally it was intended to calculate a cumulative PASI-like score for every 
experiment. However, this was hard to replicate, mainly due to mice having variable 
amount of hair after shaving, which affected the redness parameter. It was also quite 
hard to use scaling as a reliable readout, due to mice scratching and biting each other. 
To circumvent this and to monitor the course of the disease daily, only the thickness 
of the ears and the back skin were measured. Additionally, the mass of the mice was 
also measured every day.  To adjust the measurements so that the results could be 
replicated in other experiments percentage change in all parameters were calculated.  
The clinical courses of the inflammation of the ear and the back skin were overall 
very similar but displayed slightly different kinetics. The back skin seemed to get 
inflamed earlier and the peak of inflammation was around Days 4 and 5. At the same 
time, the peak of ear inflammation was on Day 6 (Figure 8B). Another interesting 
feature, which was observed during treatment with Aldara, was that mice lost up to 
15% of their body mass by Day 2, but at Day 6 they generally recovered to their 
starting mass. 
 
2.1.3	  Histological	  features	  of	  Aldara	  psoriasis	  
Histological analysis of the Aldara-treated back skin revealed inflammation from Day 
2 onwards, which increased in severity on Day 3, and decreased from Day 4 on. The 
ears showed very similar inflammatory pattern of inflammation, but its apex of 
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inflammation was reached by Days 4 to 5. Moreover, Aldara treatment resulted in 
hyperproliferation of keratinocytes and disturbed epidermal differentiation as 
indicated by acanthosis and hyperparakeratosis. In the dermis, a massive infiltrate of 
leukocytes could be observed (Figure 8C).  
To verify the presence of the neutrophils in the Aldara treated skin myeloperoxidase 
(MPO) staining was performed. This clearly highlighted the accumulation of 
neutrophils in the parakeratotic stratum corneum and was highly comparable to 
Munro microabscesses in human psoriasis. (Figure 8C). 
 
2.1.5	  Aldara	  psoriasis	  model	  responds	  to	  anti-­‐IL-­‐12/23p40	  treatment	  
As discussed above, this model satisfies most criteria of a good psoriasis model203,385. 
The only criterion that had not been tested in this model was the response to the well-
established antipsoriatic drugs. Ustekinumab is a monoclonal antibody against human 
IL-12/23p40, which had great success in clinical trials (73% PASI 75 at 12 weeks)432, 
and by now is the only drug of this type approved for treatment of psoriasis. To see if 
the Aldara model would be responsive to anti-IL-12/23p40, the mice were given a 
single intra peritoneal injection of 200 µg of the antibody on Day 2. Surprisingly, this 
was very successful as the mice that received the anti-IL-12/23p40 antibody had 
significantly lower inflammation compared the mice that received an isotype control 
antibody (Figure 8E). From this point onwards only the kinetics for the back skin 
thickness will be described due to strong similarities between the disease courses in 
the back skin and the ears. 
This finding and the recent report that Aldara psoriasis is responsive to NB-UVB 
therapy433 indicate that Aldara psoriasis model satisfies all of the criteria for a good 
psoriasis model203. These include epidermal changes based on keratinocyte 
hyperproliferation and altered differentiation; papillomatosis; presence of 
inflammatory cells, including T cells, DC, and neutrophils; a functional role for T 
cells; altered vascularization; and responsiveness to anti-psoriatic treatments. 
Additionally, this finding is in line with the earlier report where Aldara skin 
inflammation was dependent on IL-23p19385. 
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Figure 8. The Aldara psoriasis model characterisation. (A) Images show a 
representative back skin of a WT mouse treated for 5 days with Aldara or control 
cream. (B) Kinetics of Aldara-induced skin inflammation was quantified over 6 days 
as percentage increase in the thickness of ear (left) and back (right) skin. Data are 
shown as the mean percentage ± SEM (n=4). (C) Back (day 3) and ear (day 5) skin 
sections of Aldara treated vs. control treated mice were stained with H&E and for 
anti-MPO. Original magnification: x40 Scale bar: 50 µm. (D and E) WT mice were 
treated with Aldara and anti–IL-12/23p40 mAb or isotype control on day 2. (D) 
Kinetics of skin inflammation as percent increase in thickness over 6 days (n = 4). (E) 
Skin sections were stained with H&E and anti-MPO. Scale bars: 100 µm. 
Results    
 
 56 
2.2	  The	  signaling	  pathways	  involved	  in	  Aldara	  psoriasis	  
As mentioned above the active ingredient of Aldara is Imiquimod, which is a strong 
TLR7 and a weak TLR8 agonist. Currently, it is believed that mouse TLR8 is 
nonfunctional. However, Imiquimod itself has other activities such as interference 
with the adenosine signalling434 and direct apoptotic activity431.  
2.2.1	  Aldara	  psoriasis	  is	  not	  completely	  dependent	  on	  TLR7	  
To elucidate the mode of action of Aldara, tlr7-/- and myd88-/- mice were treated with 
the cream. Both mutant mouse strains did not develop psoriasiform lesions, as they 
completely lack leukocyte infiltration into the tissue and inflammation, unlike the 
wild-type counterparts. At the same time only the lack of MyD88 resulted in an 
almost complete absence of Aldara activity, as seen by the absence hyperproliferation 
of keratinocytes upon cream treatment. TLR7 deficiency does allow such a 
hyperproliferatory response to develop, but it does not lead to inflammation (Figures 
9A and B). Thus overt TLR7 signalling seems to be the main immunologic trigger of 
psoriasiform plaque formation in the Aldara psoriasis model, but TLR-7/MyD88 
independent Aldara activity was also confirmed. Furthermore, MyD88 is an adaptor 
molecule in a variety of pathways, including the signalling of IL-1 and IL-18 
receptors131,435,436, which could be the reason for the differential phenotypes in the two 
mouse strains437.  Finally, this could also be the result of additional active ingredients 
in the Aldara cream formulation (M. van den Broek, unpublished observations). 
Another interesting observation was that the mice lacking TLR7 or MyD88 were 
resistant to the weight loss due to Aldara treatment, unlike wild-type mice (Figure 
9C). Therefore, it seems that the systemic effects of Aldara are mediated exclusively 
through the TLR7 agonistic activity of Imiquimod. 
 
2.2.2	  Type	  I	  IFNs	  do	  not	  play	  a	  role	  in	  Aldara	  psoriasis	  
As described above pDCs are a small DC subset circulating through peripheral blood 
and secondary lymphoid organs. They represent key innate effector cells during 
antiviral immune responses due to their capacity to secrete large amounts of type-I 
IFN upon TLR7/9 stimulation160. There is plenty of evidence that pDC-derived IFN-I 
signaling is an upstream event preceding autoimmune inflammation and psoriasis 
development76,117,374. However, these findings were not supported in psoriasis clinical 
trials targeting IFN-α. 
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To test if type I IFNs play a role in the Aldara psoriasis, IFNAR-/- mice were 
compared to the wild-type mice. Interestingly, there was no difference between the 
two mouse strains macroscopically as well as histologically (Figures 9A and B). This 
points at pDCs and their effector cytokines type I IFNs not playing a role in Aldara 
psoriasis. 
On the other hand, IFNAR-/- mice were still resistant to the weight loss, previously 
observed in tlr7-/- and myd88-/- mice (Figure 9C). This implies that the TLR7 agonistic 
activity of Imiquimod in the Aldara cream is partially responsible for the observed 
inflammation, but primarily mediates the systemic effects of the Aldara cream 
through TLR7-MyD88-IFN I pathway. 
 
 
Figure 9. The signaling pathways involved in Aldara psoriasis (A-C) Comparison 
of WT versus tlr7-/- and myd88-/- mice (A) Kinetics of Aldara-induced skin 
inflammation (B) H&E staining. Original magnification: x40 Scale bar: 100 µm (C) 
Kinetics Aldara induced change in mass. (D-F) Comparison of WT and IFNAR-/- 
mice. (D) Kinetics of Aldara-induced skin inflammation (E) H&E staining. Original 
magnification: x40 Scale bar: 200 µm (F) Kinetics of mass change. 
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2.3	  The	  roles	  of	  IL-­‐17A,	  IL-­‐17F	  and	  IL-­‐22	  in	  Aldara	  psoriasis	  
Previous report have shown upregulation of IL-17A, IL-17F and IL-22 mRNA in the 
skin of the Aldara treated mice after 72 hours385. This is in line with the findings in 
human psoriasis patients that have increased numbers of IL-17 and IL-22 producing 
cells in circulation86. In this model it is also supported by the fact that mice lacking 
IL-23 were resistant to Aldara385, as well as successful treatment of Aldara psoriasis 
with anti-IL-12/23p40 antibody and implicates IL-23/TH17 axis. 
 
2.3.1	  IL-­‐17A,	  IL-­‐17F	  and	  IL-­‐22	  are	  produced	  in	  the	  inflamed	  skin	  
The verification if the upregulation of the mRNA yielded increases in IL-17A, IL-17F 
and IL-22 on protein level was required. The skin lymphocytes from the Aldara 
treated and control mice were restimulated with PMA and ionomycin and stained 
intracellularly for IL-17A, IL-17F and IL-22. IL-17A and IL-17F producing cells 
were very abundant in the skin of Aldara treated animals, but not in controls. 
Interestingly, IL-17F production was about two-fold higher than that of IL-17A. 
There was also some production of IL-22, which also was only observed in Aldara 
treated animals (Figure 10A). 
 
2.3.2	  IL-­‐17A,	  IL-­‐17F	  and	  IL-­‐22	  play	  differential	  roles	  in	  the	  Aldara	  psoriasis	  
Earlier findings showed that IL-17RA deficient mice are resistant to Aldara 
psoriasis385. However, it is known that IL-17RA is not only the receptor for IL-17A 
and IL-17F, but also for IL-17C and IL-17E256. To check the differential roles of IL-
17A, IL-17F and IL-22, single cytokine knockout animals were treated with Aldara 
and compared to wild-type counterparts and controls. Significant reductions in 
psoriasiform phenotype were observed in all of the mutant mouse strains, compared to 
wild-type mice. Analysis of skin thickness at peak disease (day 4) underlined the 
extent of the differences in lesion development (Figure 10B). Moreover, histological 
analysis of the inflammation revealed significant reductions in acanthosis in Il17a-/-, 
Il17f-/-, Il22-/- mice compared to wild-type mice, with the most pronounced effects 
observed in mice lacking IL-17F and IL-22 (Figure 10C). 
 
2.3.3	  IL-­‐17AF	  heterodimers	  are	  more	  abundant	  in	  Aldara	  treated	  mice	  
The fact that there were more skin-invading cells secreting IL-17F than IL-17A is in 
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line with the stronger disease resistance in Il17f–/– compared with Il17a–/– mice. IL-
17AF heterodimers have been described to share the biological properties with IL-
17A and IL-17F438.  
This could explain the differential phenotype in mice lacking IL-17A vs. IL-17F. To 
verify if IL-17AF heterodimers are abundant after Aldara treatment a bead microarray 
analysis of the supernatants from restimulated lymph node and ear lymphocytes was 
performed. Indeed, the abundance of IL-17AF heterodimers was significantly 
increased in the lymph nodes of Aldara-treated mice, compared to controls. At the 
same time, no significant difference was observed in the ears (Figure 10D). 
Figure 10. The roles of IL-17A, IL-17F and IL-22 in Aldara psoriasis. (A) Dot plots 
display the secretion of IL-17A, IL-17F, and IL-22 among CD45+ cells from the skin of 
wild-type mice on day 5 of Aldara treatment. (B and C) WT, Il17a–/–, Il17f–/–, and Il22–/– 
mice were treated with Aldara or control cream for 5 days. Scatter plot shows percent 
increase in skin thickness (n = 4) (B). Skin sections of Aldara-treated mice taken on day 6 
(C) were stained with H&E. Scale bar: 100 µm. (D) IL-17AF heterodimer concentration 
was measured in the supernatant of LN or skin cells cultured for 24 hours using IL-17AF 
FlowCytomix Simplex kit. 
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2.4	  The	  cellular	  sources	  of	  IL-­‐17	  and	  IL-­‐22	  
Thus far the production of IL-17A, IL-17F, and IL-22 seemed to be crucial for the 
psoriasiform plaque formation in Aldara treatment model. It is also in line with the 
paradigm of the TH17 cells242, which were reported to produce the above effector 
cytokines in this model385. However, due to the rapid disease development other and 
especially innate sources of IL-17 and IL-22386 could be involved in Aldara psoriasis.  
To determine the main producers of these critical cytokines, Rorc-Cre x EYFP fate-
mapping mouse strain439 was used. In these mice EYFP gene flanked by loxP sites is 
inserted into ROSA26 locus. At the same time Cre recombinase is expressed under 
the Rorc promoter. Therefore, any cell that had at any point during its life cycle 
expressed Rorc, would be EYFP positive (Figure 11)440. Rorc is the gene for 
transcription factor Rorγt, which is the main transcription factor for IL-17A and IL-
17F209. Even though no putative binding sites for Rorγt were found on the promoter 
region of the il22 gene, it has been reported that mice and cells lacking Rorc do not 
produce IL-22441. Therefore, the vast majority of IL-17 and IL-22 producing cells in 
Rorc-Cre x EYFP mice would also be EYFP positive. 
 
	  
2.4.1 γδ	  T	  cells	  are	  the	  main	  producers	  of	  IL-­‐17	  and	  IL-­‐22	  in	  Aldara	  psoriasis	  
To determine the cell types that are responsible for the production of IL-17 and IL-22 
 
	  	  	   
Figure 11. The mechanism behind Rorc-Cre x EYFP fate-mapping mouse. “RORγt-
fate map mice” (Rorc(γt)-CreTg;Rosa26REyfp/+) allow the detection of cells that have 
expressed RORγt at any time of their lineage commitment (EYFP+). Adapted from 
Vonarbourg and Diefenbach 2012. 
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in the skin of Aldara treated mice the lymphocytes from the skin of these mice were 
restimulated and intracellularly stained for IL-17 and IL-22. Subsequently, to 
determine the main producers of these cytokines gating was performed on cytokine 
and EYFP double positive cells. As expected, the primary source of these cytokines 
were CD3+ T cells (Data not shown). Interestingly, only a very small proportion of 
the cytokine producers were CD4+ cells. However, around 80% of IL-17A and 
approximately 50% of IL-22 were produced by γδ T cells (Figures 12A and B). 
 
2.4.2	  γδ	  T	  cells	  are	  increased	  in	  the	  skin	  of	  Aldara	  treated	  mice	  
Thus far it was determined that γδ T cells are the main producers of the effector 
cytokines in Aldara psoriasis. Therefore these cells needed to be characterised in 
greater detail. The murine epidermis is populated by a unique population of γδ T cells, 
which are also called dendritic epidermal T cells (DETCs). These cells have been 
implicated in wound healing of the skin442, but apart from one study412 have not been 
reported to produce IL-17. At the same time it was recently reported that murine 
dermal resident γδ T cells express Rorγt and are potent producers of IL-17418,419. 
To understand the roles of each subset during the development of Aldara psoriasis γδ 
T cells in the Aldara treated vs. control skin were analysed. The DETCs are Vγ5+ and 
it was shown that the primary population of dermal resident γδ T cells are Vγ4+419. 
The analysis revealed two distinct populations of TCRγδ+ cells in the skin. 
Interestingly, the TCRγδhigh cells remained constant, while TCRγδmedium cells were 
substantially increased in the skin of Aldara treated mice (Figure 12C). As expected, 
TCRγδhigh cells were found to be exclusively Vγ5+ DETCs, while TCRγδmedium were 
represented primarily by Vγ4+ cells (Figure 12D). After analysing the two γδ T cell 
populations in greater detail it was determined that the percentage and the absolute 
numbers of DETCs remained relatively constant between Aldara treated and control 
skin. At the same time the Vγ4+ proportion and the absolute numbers were 
significantly increased in the skin of Aldara compared to control treated mice (Figures 
12E and F). 
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2.5	  γδ	  T	  cells	  are	  the	  main	  drivers	  of	  the	  Aldara	  psoriasis	  
So far the results are in line with the recent findings that γδ T cells are a potent source 
of IL-17 and IL-22 in models of autoimmunity386,410,416. However, the roles of TH17 
cells, CD8+ and Tregs have not been excluded. Moreover, the exact roles of Vγ5+ 
DETCs vs. Vγ4+ have not been established. It is possible to differentially target αβ 
and γδ T cells in mice through knockouts of the TCR β and δ chains, respectively. But 
Figure 12. RORγt+ γδ T cells are the main producers of IL-17A, IL-17F, and IL-22 in 
psoriasiform plaques. (A) Intracellular cytokine staining in the skin of Rorc-Cre × EYFP 
mice after 5 days of Aldara treatment, gated on CD45+ cells (n = 3), with (B) scatter plots 
showing percent distribution (n = 3). (C) Dot plots of different TCRγδ+ cell populations 
in the skin of WT mice treated with Aldara, analyzed on day 5 gated on CD3+ cells (n=4). 
(D) Dot plots of Vγ chain use by different γδ T cell populations in the skin of WT mice 
treated with Aldara, gated on CD3+ cells (n=3). (E-F) Plots display the percentages (E) 
and absolute cell number (F) of Vγ5+ and Vγ4+ cells among CD45+ cells isolated from 
the ear skin of WT mice treated with Aldara or control cream for 5 days (n=3). 
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there are a couple of drawbacks to this method. Firstly, TCRb-/- mice lack Treg cells, 
together with the helper and the cytotoxic T cells. Secondly, these mice have higher 
abundance of γδ T cells. Finally, TCRd-/- mice lack all subsets of γδ T cells, thus 
making it impossible to study differential roles of Vγ5+ DETCs and Vγ4+ cells in 
Aldara psoriasis.  
 
2.5.1	  γδ	  T	  cells,	  but	  not	  TH17	  cells	  initiate	  Aldara	  psoriasis	  	  
To establish the relative roles of αβ and γδ T cells in Aldara psoriasis, the responses to 
Aldara were compared in Tcrb–/–, Tcrd–/–, and wild-type mice. Tcrb–/– mice developed 
inflammation similar to wild-type mice. In contrast, Tcrd–/– mice had drastically 
lower, but still noticeable inflammation in the skin (Figure 13A). Therefore, it is clear 
that γδ T cells are the main players in Aldara psoriasis. However, residual 
inflammation in Tcrd–/– mice suggests that another cell type can be involved in Aldara 
skin inflammation. Interestingly, there was also tendency for Tcrb–/– mice to develop 
slightly more inflammation than wild-type mice. This could be explained either by 
higher frequency of γδ T cells in those mice or the lack of regulatory T cells. It is also 
possible that the γδ T cell pool in Tcrb–/– mice is altered due to the developmental 
changes in the γδ lineage in the thymus443. However, Cai and colleagues, using Tcra–
/– mice, also found them to be fully susceptible to IL-23–induced psoriasis-like plaque 
formation444, indicating that the lack transconditioning of γδ T cells does not affect 
the phenotype of Tcrb–/– mice. 
 
2.5.2	  Vγ4+	  γδ	  T	  cells,	  rather	  than	  DETCs	  produce	  IL-­‐17	  and	  IL-­‐22	  
Due to some discrepancies in the field of γδ T cell research412 and the experiments 
conducted up to this stage it can not be excluded that DETC also play a role in Aldara 
psoriasis. To further investigate which γδ T cell subset plays a more important role in 
this skin inflammation intracellular staining for IL-17 and IL-22 of the restimulated 
skin lymphocytes was performed. Gating was differentially conducted on Vγ5+ 
DETCs and Vγ4+ cells from the inflamed skin. Vγ4+ cells produced large amounts of 
IL-17 and IL-22, whereas DETCs did not (Figure 13B). This suggests that Vγ4+ cells 
drive the inflammatory skin alteration in this model. 
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2.5.3	  DETCs	  do	  not	  play	  a	  role	  in	  Aldara	  psoriasis	  
Thus far the findings strongly point at the Vγ4+ cells to be the main mediators of 
Aldara psoriasis. These cells were increased in the skin after Aldara treatment and 
were found to produce IL-17 and IL-22, which are necessary for the disease 
development. However, due to their the importance of DETCs in wound healing they 
can play a protective, rather than pathogenic role in this disease model350. To formally 
rule out the involvement of DETCs in Aldara psoriasis wild-type mice were compared 
to Il15ra–/–. In the latter strain DETCs do not develop (Figure 13C) and therefore it 
would allow to establish the relative contribution of this cells type to the Aldara-
driven inflammation. Surprisingly, there was no difference between the two mouse 
strains in response to Aldara treatment (Figure 13D). Therefore, at this point it was 
clearly established that Vγ4+ γδ T cells are the main initiators of Aldara psoriasis. 
 
Figure 13. Vγ4+ γδ T cells are the main initiators of Aldara psoriasis. 	   (A and D) 
Kinetics of Aldara-induced skin inflammation in (A) WT versus Tcrb–/– and Tcrd–/– mice 
(n = 4) (B) Staining of V4γ+ versus Vγ5+ for IL-17F and IL-22, pre-gated on TCRγδ+ cells.  
(C) Dot plots of Vγ4+ and Vγ5+ γδ T cell populations in the skin of naïve WT and Il-
15Ra-/- mice gated on TCRγδ+ cells (n=3). (D) WT versus Il15ra–/– mice (n = 3). 
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2.6	  Clonally	  expanded	  Vγ4+δ4+	  γδ	  T	  cells	  infiltrate	  the	  skin	  
In previous studies it has been shown that in mice dermal rather than circulating γδ T 
cells produce IL-17 and initiated the immune response against Mycobacterium 
tuberculosis419. On the contrary, in human psoriasis γδ T cells were shown to infiltrate 
lesional skin through expression of skin homing receptors inclusing CCR4, CCR6, 
CCR10 and CLA. Moreover, these cells produced significant amounts of IL-17 and 
were normalised in the blood after successful treatments of patients for psoriasis445. In 
the study in mice it was shown that the dermal γδ T cells are radio resistant. 
Therefore, to address the question of dermal vs. circulating γδ T cell involvement in 
the immune response the bone marrow chimera approach was used. However, after 
initially also using this approach to determine the origin of the IL-17-producing γδ T 
cells were none found in the skin of Aldara treated mice (Data not shown). This 
finding has been recently explained by the study showing that IL-17-producing γδ T 
cells can only develop in the foetal thymus446. 
 
2.6.1	  Vγ4+	  γδ	  T	  cells	  expand	  in	  the	  skin	  and	  in	  the	  lymph	  nodes	  
The second approach to address the question of the origin of IL-17-producing Vγ4+ γδ 
T cells initiating Aldara psoriasis was to identify the site of their proliferation. This 
was done by staining the cells from the draining lymph nodes and the skin of Aldara 
treated and control mice for Ki-67, which is only expressed by dividing cells447. 
However, the analysis of Ki-67 staining revealed that Vγ4+ γδ T cells expand both in 
the draining lymph nodes and in the skin of Aldara treated mice. Interestingly, CD4+ 
cells did not proliferate at either site, while DETCs seemed to have reduced 
proliferation after Aldara treatment (Figure 14A). 
 
2.6.2	  Vγ4+	  γδ	  T	  cells	  in	  the	  Aldara	  treated	  mice	  specifically	  upregulate	  CLA	  
Another approach to establish the origin of IL-17-producing Vγ4+ γδ T cells in the 
Aldara treated skin used the expression of skin homing receptors on these cells. These 
include CCR4, CCR6, CCR10448 and CLA449 and have been shown to be expressed 
by γδ T cells in psoriasis patients445. 
Neither CCR4 nor CCR10 positive γδ T cells could be found in the skin and in the 
lymph nodes of Aldara or control mice. Interestingly, the vast majority of IL-17-
producing CD27- γδ T cells were CCR6 positive, which also seems to be a marker for 
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the expression of Rorγt by the cells (Data not shown). The staining for CLA revealed 
that there were hardly any positive Vγ4+ cells in control mice. But that CLA was 
specifically upregulated on CD27- Vγ4+ cells in the draining lymph nodes of Aldara 
treated mice (Figure 14B and data not shown). This suggested that due to Aldara 
treatment the proliferating Vγ4+ T cells are specifically recruited to the skin through 
induction of CLA and possibly through CCR6-CCL20 interaction450.  
 
2.6.3	  Vγ4+δ4+	  are	  the	  primary	  skin-­‐invading	  γδ	  T	  cells	  population	  
There have been multiple reports of clonally expanded T cells found in psoriatic 
lesions282. At the same time, in the mouse model of collagen-induced arthritis it was 
shown that the primary source of IL-17 in the inflamed joints were clonally expanded 
Vγ4+δ4+ γδ T cells416. 
In depth analysis of Vγ4+CD27-CLA+ γδ T cells in the draining lymph nodes of 
Aldara treated mice revealed that the skin-homing CLA+ γδ T cells are indeed 
oligoclonal and similarly to the arthritis model were Vγ4+δ4+ (Figure 14C). 
Subsequent characterisation of the Vγ4+ in the skin of Aldara treated mice has shown 
that a substantial proportion of skin infiltrating CLA+ γδ T cells were also Vγ4+δ4+ 
(Figure 14D).  
In summary, the results so far indicate that in the Aldara psoriasis model IL-17A, IL-
17F and IL-22 are important for the disease development. The primary source of these 
cytokines were Vγ4+ γδ T cells and not the TH17 cells. Moreover, it seems that these 
cells are clonally expanded (Vγ4+δ4+) in the draining lymph nodes of Aldara treated 
mice and through upregulation of skin-homing molecule CLA are recruited to the skin 
where they cause the inflammation through production of effector cytokines IL-17 
and IL-22. These findings are also very much in line with the clinical report, in which 
IL-17-producing γδ T cells were recruited to the psoriatic skin from circulation 
through expression of CLA and other skin homing receptors445.  
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2.7	  ILCs	  are	  an	  alternative	  source	  of	  IL-­‐22	  in	  Aldara	  psoriasis	  
As previously described, innate lymphoid cells (ILCs) are a very minor population of 
lineage negative lymphocytes that has been shown to produce significant amounts of 
IL-22 and some IL-17 in certain disease models, especially in Rag-/- mice428. From 
Figures 12A and B it is clearly evident that γδ T cells are the primary producers of IL-
17 and IL-22. And from Figure 13A it is the quite apparent that they are main cell 
type responsible for the development of Aldara psoriasis. However, it is also clear that 
there is an alternative source(s) of IL-17 and IL-22. Especially in case of IL-22 there 
seems to be another cell type that significantly contributes to Aldara-induced 
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Figure 14. Clonally expanded Vγ4+δ4+ γδ T cells infiltrate the skin. (A) Vγ4+, CD4+ T 
cells and DETCs derived from the back skin and the draining lymph nodes of Control 
(shaded) vs. Aldara treated (transparent) mice on day 5 (pre-gated on CD45+ live cells) 
were analyzed for the expression of Ki-67. (B) Flow cytometric analysis of CLA and 
CCR6 expression in the draining lymph nodes of Aldara treated and control mice on day 
5, pre-gated on Vγ4+ cells. (C-D) Flow cytometric analysis of CLA+ γδ T cells (C) in the 
draining lymph nodes pre-gated on γδ T cells, and (D) in the skin, pre-gated on CD45+ 
cells. 
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psoriasis. Therefore, ILCs seem likely to be the likely source. 
 
2.7.1	  Rag1-­‐/-­‐mice	  have	  slightly	  stronger	  response	  to	  Aldara	  than	  Tcrd-­‐/-­‐	  
To address the question of the involvement ILCs in Aldara psoriasis, wild-type mice 
were compared to Tcrd-/- and Rag1-/- counterparts. The latter mice lack all 
lymphocytes that use VDJ recombination including αβ and γδ T cells. Both strains 
were relatively protected from Aldara-induced skin inflammation. However, there 
was a tendency for the Rag1-/- mice to be slightly more inflamed than Tcrd-/- (Figure 
15A). This finding implied the involvement of ILCs in Aldara psoriasis. 
 
2.7.2	  Lin-­‐	  cells	  produce	  IL-­‐22	  in	  the	  skin	  of	  Aldara	  treated	  mice	  
An unidentified population of CD3- cells was previously found to produce substantial 
proportion of IL-22 in the skin of Aldara treated mice. As ILCs are Lin- the 
lymphocytes from the skin of control and Aldara treated mice were stained for lineage 
markers CD3, CD11b, CD11c, B220 and Gr1. After restimulation these cells were 
also intracellularly stained for IL-22. Indeed, there was a small population of cells, 
which was negative for all of the lineage markers and that produced IL-22 only in the 
skin of Aldara treated mice. Interestingly, unlike the previous findings by our 
group427, these cells were NKp46- (Figure 15B). 
 
2.7.3	  ILCs	  are	  enriched	  in	  the	  spleens	  of	  Rag1-­‐/-­‐	  mice	  
Different groups use different markers to identify ILCs425,428, yet the most reliable 
method seems to be a mixture of those and involves staining for CD3, CD5, CD11c, 
B220, Thy1, Sca-1 and IL-7Ra (Data not shown). This method involves taking CD3-
CD5-CD11c-B220- cells in the first step of the gating to exclude the majority of 
lineage positive cells. As Thy1 is primarily a T cell marker451 and Sca-1 is generally 
considered to be an antigen expressed by the stem cells452 only a very small 
proportion of the remaining cells are positive for both of these markers. Finally, ILCs 
development is dependent on IL-7422,424, therefore only IL-7Ra+ cells are considered 
to be bona fide ILCs (Figure 15C).  
The above gating strategy was used to analyse the proportion of ILCs in the spleens of 
wild-type, Tcrd-/- and Rag1-/- mice. The overall proportion of the ILCs in the spleens 
was very low, and it was nearly the same for wild-type and Tcrd-/- mice. At the same 
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time, there was a significant increase in the proportion of these cells in the spleens of 
Rag1-/- mice, compared to the other two strains (Figure 15D). This finding is also in 
line with the hypothesis that ILCs are partially responsible for the induction of Aldara 
psoriasis through IL-22 production. Increased numbers of these cells in Rag1-/- mice 
could explain the tendency for slightly higher degree of inflammation in these mice 
compared to Tcrd-/- mice. 
 
2.7.4	  Increased	  upregulation	  of	  CLA	  on	  ILCs	  in	  Rag1-­‐/-­‐	  mice	  
γδ T cells were found to specifically upregulate CLA, which facilitated their 
migration to the skin in this psoriasis model and in patient studies445. The analysis of 
CLA expression on the ILCs in the draining lymph nodes of Aldara treated wild-type, 
Tcrd-/- and Rag1-/- mice revealed an increased upregulation of this skin homing 
marker in the latter strain (Figures 15E and F). Again, this further supports the role of 
ILCs in the development of Aldara psoriasis. It indicates that higher numbers of ILCs 
upregulate CLA to a higher degree to compensate for the absence of γδ T cells. 
 
2.7.5	  Increased	  production	  of	  IL-­‐22	  by	  ILCs	  in	  the	  skin	  of	  Rag1-­‐/-­‐	  mice	  
To aid the identification of ILCs the previously described Rorc-Cre x EYFP fate-
mapping mouse strain was crossed onto the Rag1-/- background. In this mouse only 
ILCs would be positive of EYFP. This fact was used to compare the ILCs in the skin 
of wild-type and Rag1-/- mice after Aldara treatment in an unbiased way. The direct 
comparison of the two fate-mapped strains not only showed an increased proportion 
of ILCs in the skin of Rag1-/- mice, but also revealed an increased production of IL-22 
by ILCs in Rag1-/- mice compared to wild-type counterparts (Figure 15G).  
 
2.8	  RORγt+	  innate	  lymphocytes	  are	  essential	  for	  Aldara	  psoriasis	  
So far there is strong evidence that ILCs mediate Aldara psoriasis inflammation in the 
absence of γδ T cells. This hypothesis is supported by increased numbers of ILCs in 
Rag1-/- mice, their increased upregulation of CLA and production of IL-22 compared 
to wild-type and Tcrd-/- mice.  
 
2.8.1	  Rag2-­‐/-­‐	  Il2rg-­‐/-­‐	  mice	  are	  resistant	  to	  Aldara	  psoriasis	  
Rag2-/- Il2rg-/- mice do not have ILCs due to their lack of IL-7 receptor signalling. At 
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the same time these mice also do not have NK cells. However, their absence was 
accounted for in the Il15Ra-/- experiment, which showed no difference in the disease 
severity compared to wild-type mice. To have a direct comparison for the role of ILCs 
in the skin inflammation wild-type, Rag1-/- and Rag2-/- Il2rg-/- mice were treated with 
Aldara. Astonishingly, Rag2-/- Il2rg-/- mice were completely resistant to Aldara-
induced skin inflammation (Figure 16A), which underlinined the role of the ILCs in 
the Aldara psoriasis initiation. 
 
 
. 
 
2.8.2	  Rorc-­‐/-­‐	  mice	  are	  completely	  resistant	  to	  Aldara	  psoriasis	  
Thus far the results showed the dependence of Aldara psoriasis on ILCs and γδ T 
Figure 15. ILCs are the alternative source of IL-22 in Aldara psoriasis. (A) Kinetics 
of Aldara-induced skin inflammation in WT versus Tcrd–/– versus Rag1–/– mice. (B) 
Cytokine staining in ILCs in the skin of Aldara- versus control-treated mice, pre-gated on 
Lin–CD45+ cells (n=3). (C) Gating strategy for ILCs, pre-gated on CD45+ cells (D) Scatter 
plots showing ILCs as a percentage of CD45+ cells (E and F) Analysis of CLA expression 
in WT vs. Tcrd-/- and Rag1-/- mice. (E) Representative FACS plots. (F) Scatter plot 
analysis. (G) Fate map analysis and IL-22 staining in the Aldara-treated skin of Rorc-Cre 
X EYFP and Rorc-Cre × EYFP × Rag1–/– mice gated on CD45+ cells. 
 
  Results 
 
 71 
cells. Both of these cell types are largely dependent on the transcription factor RORγt 
for the cytokine production of IL-17 and IL-22, which are crucial for the disease 
development. In line with this Rorc-/- mice were completely resistant to Aldara 
psoriasis and the changes in skin thickness in these mice were very similar to that of 
wild-type mice treated with the control cream (Figure 16B).  
As previously stated mice lacking transcription factor RORγt do not produce IL-17 or 
IL-22209,441.  As a result, no production of either cytokine was observed in Aldara 
treated Rorc-/- mice. This fact is especially underlined by slightly higher levels of IL-
17 produced in the skin of control treated wild-type mice compared to Rorc-/- mice 
(Figure 16C). Taken together these findings reemphasize the importance of RORγt+ 
γδ T cells and ILCs, as well as their production of IL-17 and IL-22 for the 
development of skin inflammation in Aldara psoriasis model. 
 
 
 
Figure 16. RORγt+ innate lymphocytes are essential for psoriasiform plaque 
formation. (A) WT versus Rag1–/– versus Rag2–/–Il2rg−/− mice and (B) WT versus Rorc–/– 
mice showing percentage change in skin thickness (n=3). (C) Staining for IL-17F and IL-
22 in CD45+ cells from the skin of control and Aldara-treated WT versus Rorc–/– mice (n = 
3) 
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3 Discussion 
3.1	  The	  model	  
Despite not being as authentic as the xenotransplantation model of psoriasis the 
Aldara model385 and the cytokine injection models377,380,381 present new promising 
approaches to study psoriasis. The big advantage of the Aldara model is that it is 
known to initiate psoriasis in humans170-174. Therefore one is tempted to speculate that 
unlike, the “shortcutting” method of cytokine injection, Aldara cream provides a bona 
fide psoriasis trigger. Moreover, previous385 and this studies have shown quite 
conclusively that the Aldara model satisfies all of the criteria for a good psoriasis 
model, including psoriasis model203, including: epidermal changes based on 
keratinocyte hyperproliferation and altered differentiation; papillomatosis; presence of 
inflammatory cells, including T cells, DC, and neutrophils; a functional role for T 
cells; and altered vascularisation385. It was also reported that Aldara psoriasis is 
reduced after NB-UVB treatment433. And in this study it was clearly shown that it also 
responds to anti-psoriatic drugs453, namely anti-IL-12/23p40. 
With the exception of streptococcal infections43, Aldara is one of the more verified 
triggers of psoriasis to date. The studies of the former have been quite successful and 
yielded an identity of a potential antigenic determinant recognized by the T cells in 
the psoriatic skin. Namely, it was attributed to the cross-reactivity between 
streptococcal M protein and Keratin 17282. Despite this, streptococcal studies are 
unlikely to be translated to a mouse model, which makes the Aldara model385 the one 
with the most authentic psoriasis trigger, with the exception of the 
xenotransplantation model. 
The spontaneous disease models of psoriasis have been shown to be quite unauthentic 
due to lack of their T cells dependence and poor responsiveness to anti-psoriatic 
drugs. On the other hand, the transgenic models are useful for studying certain 
pathways in isolation with some of these models achieving great authenticity and 
resemblance of psoriasis205. However, psoriasis is known to have a complex 
pathogenic mechanism, which is still not fully understood. Therefore, despite their 
usefulness, the above models, similar to cytokine injection models generally target an 
already known pro-psoriatic cytokine or growth factor to initiate the disease, rather 
than study the actual trigger that resulted in the upregulation of a cytokine or a growth 
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factor in the first place 
In this study and in others (Maries van den Broek personal communication) it has 
been shown that the pathogenic activity of Aldara is not solely driven by the agonistic 
activity of Imiquimod. This small molecule agonist of TLR7 has multiple activities 
itself, including triggering of TLR7, interaction with adenosine receptor signaling and 
direct apoptotic activity431. This has obvious advantages in that Aldara mimics a 
complex initial trigger for psoriasis. On the other hand, there are also disadvantages to 
this. Namely, it would be beneficial to delineate the initial trigger to a single stimulus 
rather than have at least four known activities for Aldara. Secondly, and more 
importantly not every person that is treated with Aldara succumbs to psoriasis, which 
is probably down to individual genetics. 
The xenotransplantation model of psoriasis still remains the gold standard of psoriasis 
models with a lot of potential and some great discoveries that can be attributed to it374. 
However, this model also has its limitations. Namely, the difficulties with obtaining 
human skin grafts, a cumbersome and labour intensive experimental procedure and 
the time it takes for the disease to develop. It also became quite apparent that some of 
the findings in the xenotransplantation model, such as blocking IFN-α have failed to 
be translated into human anti-psoriatic treatments376. This model is said to be useful 
for studying developed psoriasis, when lesional skin is transplanted or the initiation of 
psoriasis if near-lesional skin is transplanted. However, a closer at the experimental 
settings of the psoriasis development model suggests clonal expansion of the 
pathogenic T cells that have been transplanted with the skin being modeled, rather 
than genuine initiation of psoriasis. Despite Aldara mouse model currently being used 
as psoriasis initiation model it also probably has potential for studying relapses of the 
disease and its exacerbation, as these activities have been reported in patient 
studies170,171. 
As shown above there are obvious limitations to mouse models in general, especially 
looking at the differences between the human and the mouse skin (Figure 6)204,205. At 
the same time, the immune systems are also quite different161, making it difficult to 
directly translate the findings in the Aldara model into humans. This could be 
potentially circumvented by for example using humanized mice454. In light of this, the 
Aldara model may have good potential as a preclinical model for potential anti-
psoriatic drug testing. 
Even though psoriasis is a single disease there is quite a heterogeneity of psoriatic 
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phenotypes in patients (Figure 1)20, which would implicate slightly different 
mechanisms involved in their development or different genetic backgrounds of the 
sufferers. The bimodal distribution of the disease with relatively different symptoms 
complicates modeling it and makes the studies of the disease even more difficult. At 
the same time, there is no universal cure for psoriasis with the most efficacious 
therapies not achieving more than 75% of responsiveness in patients343. The Aldara 
psoriasis is responsive to those known anti-psoriatic therapies. Therefore, it probably 
is tempting to speculate that it mimics the disease of the 75% of the responders. Thus, 
studies of this model could potentially provide nearly complete understanding of the 
disease in those individuals. With the age of personalized medicine quickly 
approaching this could indeed be very useful.  
 
3.2	  γδ	  T	  cells	  are	  central	  for	  Aldara	  psoriasis	  development	  
γδ T cells are a relatively novel subset of T cells, which acts at the interface between 
innate and adaptive immunity455. Even though some of the subsets of these cells have 
restricted T-cell receptors their ligands and consequences of the TCR signaling are 
still not well studied456-458. At the same time, it is known that these cells express a 
large variety of innate receptors including TLRs409 and stress-sensors459,460.  
Psoriasis is thought to be caused by self-reactive or cross-reactive CD4+ and/or CD8+ 
cells20,282. It was previously briefly reported that γδ T cells are increased in the 
psoriatic lesions420. In this study of Aldara model these cells were clearly shown to 
play the central role in the development of skin inflammation.  The mice lacking γδ T 
cells were highly protected from the disease. Interestingly, DETCs, which are thought 
to be important for wound repair350 didn’t seem to play a role as was shown in Il15Ra-
/- mice. 
Similar to the human disease high production of IL-17A, IL-17F and IL-2286 was 
observed in the lesional skin of Aldara treated mice.  Subsequently, all these 
cytokines were shown to play a role in the disease initiation, but with quite different 
outcomes. Interestingly, mice lacking IL-17F showed much reduced skin 
inflammation compared to IL-17A mice. There are some possible explanations for 
this. It was shown the levels of IL-17AF heterodimer were increased in the Aldara 
treated mice compared to the controls. At the same time, the production of IL-17F 
two-fold higher than IL-17A. Taken together, these data indicate that the majority of 
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the disease would be mediated by IL-17F homodimers or IL-17AF heterodimers. 
Hence, in the absence of IL-17A only the heterodimers would be affected, while the 
lack of IL-17F would result in the absence of both. Therefore, much less 
inflammation. Interestingly, it was recently shown that IL-17C seems to play a role in 
Aldara psoriasis260, which could explain nearly complete resistance of IL-17RA 
deficient mice to the disease385, but some residual inflammation in IL-17A and even 
IL-17F deficient animals.  
The finding that γδ T cells produce IL-22 is a relatively rare one and the production of 
this cytokine was exclusive to the skin, but not the draining lymph nodes of the mice 
that have been treated with Aldara (data not shown). This implies that some extra 
signaling occurs in the skin, but not in the lymph nodes of the inflamed mice, 
enabling the production of IL-22. Potentially, the production of IL-22 could be 
triggered through AhR. However, its ligands are not very well studied and therefore it 
would be quite a challenge to understand if the signal may be comes from Aldara or 
from the host cells. At the same time, it could involve both keratinocytes, which have 
been shown to produce a lot of IL-1 upon activation and activated DCs that would 
produce IL-23. Both of these cytokines are potent inducers of IL-17 and IL-22 in γδ T 
cells409,410. A recent study has shown that in the absence of IL-17RA the mice get a 
delayed onset of the skin inflammation. Moreover, in that study in line with the later 
onset of the inflammation IL-22 is produced by both CD4 and γδ T cells461.  
γδ T cells have been shown to be potent and rapid producers of IL-17 and IL-22 in 
response to IL-23 and IL-1410, as well as after TLR stimulation409 and recently 
through the TCR engagement457. Due to the short disease course it was not surprising 
that γδ T cells were the main source of IL-17 and IL-22 in the Aldara model. 
Moreover, it is quite in line with the previous observations that anti-CD3 antibody 
treated and RAG-/- 2rg-/- mice had reduced skin inflammation385. Interestingly, the 
similar approach was used in the xenotransplantation model, where the disease was 
blocked by OKT3 T cell depleting antibody374, which also targets γδ T cells462. And 
both studies have implicated CD4+ T cells in the disease development. Moreover, a 
study that slightly preceded ours was able to show that IL-17-producing γδ T cells are 
indeed pivotal for the development of Aldara psoriasis444. These findings were also 
duplicated and reinforced in the cytokine injection model380,444. Therefore, our results 
that show γδ T cells being important for the development of Aldara psoriasis are 
further reinforced. 
Discussion   
 76 
One of the more difficult questions of this study was to identify the source of γδ T 
cells. This was particularly tough due to inability to use bone-marrow chimeras to 
study this phenomenon418,446. Interestingly, recent report actually used this method to 
show a role for IL-17-producing dermal-resident radioresistant γδ T cells in 
subcutaneous immunization419. However, in the light of the above findings that IL-17-
producing γδ T cells cannot be reconstituted with bone marrow446 would make the 
dermal resident γδ T cells the only remaining IL-17-producing γδ T cells in those 
mice.  
It was recently reported that circulating IL-17-producing γδ T cells were reduced in 
the blood of psoriasis patients and that these cells were rapidly recruited to the 
perturbed skin through upregulation of skin-homing receptors, including CLA. 
Moreover, the levels of these cells in the blood were restored after successful 
treatment of psoriasis in those patients445. Using a similar approach we were able to 
show that γδ T cells specifically proliferate in the Aldara treated mice and that this 
could take place both in the skin and in the draining lymph nodes. At the same time, 
skin homing molecule CLA was also specifically upregulated in the draining lymph 
nodes of Aldara treated mice. Moreover, CLA+ γδ T cells were also found in the 
lesional skin of Aldara treated mice. These findings are quite in line with the patient 
studies and therefore indicate that IL-17-producing γδ T cells can be recruited to the 
stressed skin and potentially initiate a disease like psoriasis. 
In the mouse model of collagen-induced arthritis it was found that the main source of 
IL-17 were oligoclonal γδ T cells. Those were responsible for the exacerbation of the 
disease416. In human psoriasis multiple reports have shown oligoclonality of T cells in 
psoriatic lesions282. Interestingly, in our study CLA+ γδ T cells in the draining lymph 
nodes were also nearly exclusively oligoclonal Vγ4+δ4+. At the same time, a 
population of CLA+ γδ T cells in the lesional skin was also Vγ4+δ4+, suggesting some 
specific and most likely host derived antigen recognition by these cells. However, a 
follow up study of the arthritis model was able to show that it is the mycobacteria 
from Complete Freud’s Adjuvant (CFA) that were important for the IL-17 production 
by these cells. This cytokine production was also dependent on TLR adaptor MyD88 
and the route of administration, favouring subcutaneous or intradermal route. The 
subsequent conclusions suggested that it is the dermal γδ T cells, through their 
expression of TLRs recognize mycobacteria in the CFA and then migrate to the 
draining lymph nodes and expand in a clonal fashion1. Our model is quite similar in a 
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way that the stimulus is applied to the skin and could even fit the proposed model, 
especially due to our finding that MyD88 deficient animals were resistant to the 
Aldara psoriasis. However, it seems quite unlikely that the Aldara triggered γδ T cells 
would first migrate from the dermis to the draining lymph nodes, then clonally 
expand there, upregulate CLA and subsequently return to the skin to cause the 
inflammation. What seems more likely is that in both cases MyD88 is important for 
the dendritic cells that recognize CFA or Aldara and upon activation migrate to the 
draining lymph nodes and promote the expansion of Vγ4+δ4+ oligoclonal cells, as well 
as upregultion of CLA. This theory is further reinforced by our findings that MyD88 
in Aldara model is only required in the conventional DCs (data not shown). 
As mentioned above the Aldara model mimics the initiation of psoriasis, whereas in 
patient studies the plaques are more likely to be well developed and therefore 
different.  This means that the Aldara model does not in particular contradict the 
findings of CD4 and CD8 cells in the established psoriatic plaques of patients, but 
rather complements it. This idea is also favoured by the findings that γδ T cells are 
rapidly recruited to the perturbed human skin445 and are increased in psoriatic 
lesions420,445. Interestingly, there has been a report of TLR7 being expressed by 
human γδ T cells463. Additionally, these cells were shown to express TLR2409. 
Interestingly, this PRR have also been shown to recognize streptococcal M protein464. 
Together with the findings in mice that γδ T cells promote CD4419,465 and CD8414 
responses, as well as their potential function as an APC in humans466 leaves quite a bit 
of room for speculation about the exact mechanism and roles of γδ T cells in the 
Aldara psoriasis and the human disease initiation processes. 
Overall, the findings in this model are also quite complementary to the clinical 
efficacy of targeting the IL-23/IL-17 pathway345-347,467. A closer look at evolution 
further supports the idea that IL-17 is an innate cytokine as ancestors of this gene-
family is preserved among invertebrate species392. Therefore it is not unexpected that 
more innate-like γδ T cells would be the main source of this cytokine, rather than the 
conventional adaptive TH17 cells. It remains unclear whether γδ T cells also play a 
part in the chronification and relapses of psoriasis. Broad neutralization of a specific 
cytokine can be effective, but to more specifically target the pathogenic entity in 
psoriasis and other diseases of epithelial barriers (such as Crohn’s disease) and to 
develop curative therapeutic strategies, more preclinical work is needed to better 
understand the pathogenesis of epithelial-inflammation disorders. 
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3.3	  Innate	  lymphoid	  cells	  
ILCs have been shown to be rapid producers of IL-17, but more of IL-22 in response 
to IL-23 in many mouse models that lack T and B lymphocytes245,428,468. The similar 
findings are true for our study where they were major contributors to γδ T cell IL-22 
production. This model is also dependent on IL-23 as IL-23p19 deficient mice were 
resistant to the skin inflammation385. Moreover, the role of ILCs was further 
supported by the findings of another group that have shown the dependence of Aldara 
inflammation on an innate source of IL-22469. 
However, the exact nature of the role of ILCs still remains unclear. They are 
increased in numbers in RAG-/- mice and therefore seem to play an important role in 
those models. But are they really a significant and important contributors of cytokine 
production under normal conditions and during inflammation such as psoriasis? Or 
are the ILCs may be more rapid censors of external pathogenic threat and cytokine 
producers than γδ T cells? To answer these questions and many others specific 
targeting of these cells would be required. Unfortunately, current understanding of 
these cells and their receptors hardly allows that and thus more research into their 
development, cell-specific markers and transcription factors are required. 
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4 Conclusions 
In psoriasis, the current notion that IL-23 induces TH17 cells stems from the 
observation that activated T cells are a major part of the skin-infiltrating immune cells 
and are a known source of IL-17 and IL-22. Only recently have innate lymphocytes 
been acknowledged to be highly effective producers of these mediators. Our data 
show that Rorγt-dependent ILCs and γδ T cells are necessary and sufficient to drive 
Aldara psoriasis in mice through the collective delivery of IL-17A, IL-17F, and IL-22 
to the skin. Without dismissing adaptive immune processes in the etiology of 
psoriasis, our study does establish the sufficiency of a dysregulated innate immune 
compartment for psoriatic plaque formation. Thus, our proposed paradigm of lesion 
development not only provides a new basis for understanding the therapeutic efficacy 
of new biological drugs to treat human psoriasis, but may also lead to more in depth 
research on γδ T cell and ILC involvement in the human disease (Summarized in 
Figure 17). 
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Figure 17. Initiation of psoriasis by γδ  T cells and ILCs. Microbial insults, toxic 
substances other cellular stress lead either to direct activation of DCs through pattern 
recognition receptors (PRRs), athogen-associated molecular patterns (PAMPs) or 
indirectly through keratinocyte disturbances (IL-1 and TNF). Stress-sensing DCs produce 
IL-23, which activates γδ T cells and ILCs and though transcription factor Rorγt+ produce 
proinflammatory TNF, IL-17 and IL-22. IL-22 acts on keratinocytes inducing their 
proliferation and at the same time acts synergistically with IL-17 to promote production of 
antimicrobial peptides on keratinocytes. At the same time TNF and IL-17 trigger 
keratinocyte and more DC activation. This leads to yet more TNF production, 
upregulation of adhesion molecules (e.g. CD62E ligand for CLA), angiogenesis and 
chemokine production. These chemokines include CXCL1 and CXCL8, responsible for 
the recruitment of neutrophils, as well as CCL20, a CCR6 ligand expressed by γδ T cells 
and ILCs, resulting in a self-amplifying inflammatory loop. Syringes indicate current 
available anti-cytokine therapies for psoriasis. 
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4 Methods 
4.1	  In	  vivo	  
4.1.1	  Animals	  
C57BL/6 mice were obtained from Janvier. RorcGFP/GFP (in text referred to as Rorc–/–), 
Tcrβδ–/–, Rag1–/–, and Rag2–/–Il2rg−/− mice were purchased from The Jackson 
Laboratory. Tcrb–/– and Tcrd–/– mice were bred from Tcrβδ–/– mice. Rorc-Cre crossed 
with Rosa26-stop-eYFP mice (called Rorc-Cre × EYFP mice herein) were provided 
by A. Diefenbach (University of Freiburg, Freiburg, Germany), Il17a−/− mice by Y. 
Iwakura (University of Tokyo, Tokyo, Japan), Il17f–/– mice by Merck Serono S.A., 
Il22−/− mice by J.C. Renauld (Université Catholique de Louvain, Yvoir, Belgium), 
Il15ra-/- mice were provided by S. Bulfone-Paus (University of Giessen, Giessen, 
Germany). All animals were kept in house under specific pathogen–free conditions at 
a 12hour light/dark cycle with food and water provided ad libitum. All animal 
experiments were approved by the swiss cantonary veterinary office (33/2010). 
	  
4.1.2	  Treatments	  
Briefly, The mouse back was shaved, and a daily dose of 50 mg of Aldara (5% IMQ 
cream; 3M Pharmaceuticals) or control vehicle cream (Soft Kreme KA, 
Kantonsapotheke Zürich) was applied on the back and 5 mg to each ear for 7 days 
unless otherwise indicated. Anti–IL-12/23p40 treatment was performed by i.p. 
injections of the mice with 200 µg/mouse rat anti–mouse IL-12/23p40 mAb (C17.8) 
and respective IgG2A isotype control antibody (2A3, both Bio X Cell) on day 2 of 
Aldara application. 
	  
4.1.3	  Scoring	  	  
The skin and ear thickness were measured every day using caliper (Mitutoyo). The 
changes in skin and ear thickness were converted into percentage changes to make the 
differences between the experiments comparable to each other and plotted on scatter 
plots against days to show the disease course 
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4.2	  In	  vitro	  
4.2.1	  Cell	  isolation	  and	  preparation	  
Animals were euthanized with CO2 and 4 cm2 of the back skin and whole ears were 
collected. These were cut into small pieces with scissors and digested with 1 mg/ml 
collagenase type IA and 100 µg/ml DNase (Sigma-Aldrich) for 60 minutes at 37°C 
and 5% CO2, followed by the addition of EDTA (final concentration 5mM) to stop the 
reaction. Isolation of leukocytes from spleens and the lymph nodes involved teasing 
them apart using frosted glass slides. Both were followed by filtering through 70-µm 
cell strainers (BD) and washed with PBS to obtain single-cell suspensions. 
	  
4.2.2	  Surface	  staining	  for	  flow	  cytometry	  
To stain the cells single cell suspensions were incubated with antibodies for 20 
minutes at 4°C in the dark. Antibodies used: B220 (RA3-6B2), CD11b (M1/70), 
CD11c (HL3), CD45 (30-F11), CD3 (17A2), CD4 (GK1.5), CD27 (LG.3A10), CLA 
(HECA-425), Gr-1 (RB6-8C5), CCR6 (29-2L17), NKp46 (29A1.4), TCRγδ (GL3), 
Vγ4 (UC10A6) and Vγ5 (536), (BD, eBioscience, R&D and Biolegend). The cells 
were washed twice with PBS and resuspended in 200 µl of PBS for acquisition. 
 
4.2.3	  Intracellular	  cytokine	  staining	  
For intracellular cytokine staining, cells were restimulated at 37°C and 5% CO2 in 
Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco or PAN Biotech). 
RPMI 1640 was supplemented with 10% FCS and Phorbol 12-myristate 13-acetate 
(50ng/ml) (Applichem), Ionomycin (500ng/µl) (Invitrogen) and Monensin (1µl/ml 
medium, GolgiStop™, BD) for restimulation and to block intracellular transport. 
After regular surface staining, cells were permeabilized using Cytofix/Cytoperm™ 
(BD) for 15 min. After washing the cells twice with diluted Perm/Wash™ (BD) 
buffer the cells were stained intracellularly for 20 minutes at 4°C in the dark. 
Antibodies used: IL-17A  (TC11-18H10.1) (Biolegend) and IL-17F (eBio18F10) 
(eBioscience) and IL-22 (Genentech). After staining the cells were again washed 
twice with diluted Perm/Wash™ buffer and once with PBS and resuspended in 200 µl 
of PBS for acquisition. 
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4.2.4	  Ki-­‐67	  staining	  
The cells were isolated as described above and pelleted. While vortexing, 5 ml of cold 
70% - 80% ethanol was added drop by drop into the cell pellets. The cells were 
incubated at -20oC for 2 hours. The fixed cells were washed twice in 30 ml of wash 
buffer (PBS with 1% FBS, 0.09% NaN3 pH7.2). The cells were stained with anti-Ki-
67 antibody (20Raj1) (eBioscience) diluted 1:30 in PBS for 20 minutes at 4°C in the 
dark. Afterwards the cells were washed with PBS twice and resuspended in 200 µl of 
PBS for acquisition. 
 
4.2.5	  Preparation	  of	  samples	  for	  IL-­‐17AF	  heterodimer	  bead	  array	  
The cells from ears and lymph nodes were restimulated at 37°C and 5% CO2 in RPMI 
supplemented with 10% FCS and Phorbol 12-myristate 13-acetate (50ng/ml) 
(Applichem), Ionomycin (500ng/µl) (Invitrogen) and Monensin (1µl/ml medium, 
GolgiStop™, BD) for 5 hours to stimulate cytokine secretion. Afterwards the 
supernatants were collected for bead array. 
 
4.2.6	  Bead	  array	  IL-­‐17AF	  heterodimer	  detection	  
The volumes of the reagents for the desired numbers of samples were calculated of 
reagent using FlowCytomix Pro Software (eBioscience). The lyophilized standard 
was reconstituted by adding distilled water according to the label on the standard vial 
to a final concentration of 40 ng/ml. The tube was swirled thoroughly to ensure 
quantitative solubilization of contents. 10 µl of reconstituted standard was added to a 
vial and filled up to the final volume of 200 µl with Assay Buffer (PBS with 1% 
BSA). 100 µl Assay Buffer was added to 6 tubes. 50 µl of standard was transferred 
from 1 to tube 2, mixing the contents of tube 2 and transferred 50 µl to tube 3. The 
procedure was repeated to create a row of 7 standard dilutions. The vial containing 
Allophycocyanin fluorescent anti-IL-17A monoclonal beads was vortexed for 5 
seconds to resuspend the beads thoroughly. The beads were pipetted up and down and 
1/20 of final volume was pipetted into a vial and filled up to the final volume with 
assay buffer. The beads were washed once. 1/20 of final volume of biotin conjugated 
anti-IL-17F polyclonal antibody was pipetted into a vial and filled up to the final 
volume with assay buffer. Streptavidin-Phycoerythrin (PE) was diluted 1:30 in assay 
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buffer. 
All tests were performed in duplicates. 25 µl of Standard Mixture dilutions 1 to 7, 
assay buffer and samples were added to respective tubes. 25 µl of bead mixture and 
50 µl of Biotin-anti-IL-17F were added to all tubes. The contents of the tubes were 
mixed thoroughly and incubated for 2 hours at room temperature. After the incubation 
the samples were washed twice with 1 ml of assay buffer. To detect the beads bound 
to IL-17AF heterodimers 50 µl of Streptavidin-PE was added to each tube and 
incubated at room temperature for 1 hour. The samples were again washed twice with 
assay buffer and resuspended in 200 µl of assay buffer for acquisition. The acquired 
data was analysed using FlowCytomix Pro Software. 
 
4.2.7	  Splenocyte	  cultures	  
Splenocytes from Rorc-Cre X YFP X Rag1-/- mice were cultured at 106/ml in 
complete RPMI, supplemented with DMSO (1:1000), Aldara (final concentration 
2µg/ml), Imiquimod (Sequoia Research Products) (final concentration 0.1µg/ml), both 
initially dissolved in DMSO or DMSO (1:1000) and IL-23 (20ng/ml).  
	  
4.2.8	  Flow	  cytometry	  and	  analysis	  
Beads and cells were acquired with FACS Canto II or FACS LSRII Fortessa (BD). 
Post-acquisition analysis of fluorescently stained cells was performed with FlowJo 
(Tree Star) software version 9.2. 
 
4.2.9	  Histology	  
For histology, animals were euthanized with CO2, The skin or the ears were fixed in 
4% Formalin, embedded in Paraffin and 3µm sections were processed for H&E 
staining Deparaffinized sections were stained using H&E. Immunohistological 
staining for MPO (1:100, rabbit, Thermo Scientific) was performed by a Ventana 
Benchmark XT automated staining system according to the manufacturer’s guidelines 
 
4.3	  Statistical	  analysis	  	  
For For disease severity, differences between groups were evaluated by 2-way 
ANOVA with Bonferroni’s post hoc test. For analysis of scatter plots of maximum 
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thickness comparing ≥3 groups of mice, 1-way ANOVA with Bonferroni’s post-test 
was used. Differences between two sets of data were evaluated by 2-tailed Student’s t 
test. Data represent mean ± SEM. P ≤ 0.05 was considered statistically significant. All 
statistics were done using GraphPad Prism (GraphPad Software).  
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